furonaphthodioxole - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	furonaphthodioxole	go back to main search page
Accession:	CHEBI:50307	browse the term
Synonyms:	related_synonym:	furonaphthodioxoles

show annotations for term's descendants Sort by:
Rat (689) Mouse (696) Human (712) Chinchilla (0) Bonobo (0) Dog (1) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (689)

deoxypodophyllotoxin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetyl-CoA carboxylase alpha

increases phosphorylation
multiple interactions

deoxypodophyllotoxin results in increased phosphorylation of ACACA protein
deoxypodophyllotoxin inhibits the reaction [Dietary Fats results in decreased phosphorylation of ACACA protein]
deoxypodophyllotoxin inhibits the reaction [T0901317 results in increased expression of ACACA mRNA]

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

G

fatty acid synthase

multiple interactions

deoxypodophyllotoxin inhibits the reaction [T0901317 results in increased expression of FASN mRNA]

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

glutamic--pyruvic transaminase

multiple interactions

deoxypodophyllotoxin inhibits the reaction [Dietary Fats results in increased activity of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

stearoyl-CoA desaturase

multiple interactions

deoxypodophyllotoxin inhibits the reaction [T0901317 results in increased expression of SCD mRNA]

NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562

G

sterol regulatory element binding transcription factor 1

multiple interactions

deoxypodophyllotoxin inhibits the reaction [Dietary Fats results in increased expression of SREBF1 protein]
deoxypodophyllotoxin inhibits the reaction [T0901317 results in increased expression of SREBF1 mRNA]; deoxypodophyllotoxin inhibits the reaction [T0901317 results in increased expression of SREBF1 protein]; dorsomorphin inhibits the reaction [deoxypodophyllotoxin inhibits the reaction [T0901317 results in increased expression of SREBF1 protein]]

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

serine/threonine kinase 11

increases phosphorylation

deoxypodophyllotoxin results in increased phosphorylation of STK11 protein

NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315

etoposide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

affects response to substance
multiple interactions
increases expression

ABCB1 exon polymorphism affects the susceptibility to Etoposide
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [Celecoxib results in decreased expression of ABCB1] which results in increased susceptibility to Etoposide
Etoposide results in increased expression of ABCB1 mRNA; Etoposide results in increased expression of ABCB1 protein

PMID:12969965 PMID:15239124 PMID:19047049 PMID:19562670 PMID:27570640 More...

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily C member 1

affects response to substance
multiple interactions
increases expression
decreases uptake
decreases response to substance

ABCC1 protein affects the susceptibility to Etoposide
Glucose inhibits the reaction [Sodium Azide inhibits the reaction [ABCC1 protein results in decreased uptake of Etoposide]]; Sodium Azide inhibits the reaction [ABCC1 protein results in decreased uptake of Etoposide]; Verapamil inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; Verapamil inhibits the reaction [ABCC1 protein results in decreased uptake of Etoposide]
Etoposide results in increased expression of ABCC1 mRNA
ABCC1 protein results in decreased susceptibility to Etoposide; ABCC1 results in decreased susceptibility to Etoposide
[GCLC protein co-treated with GCLM protein] promotes the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; [MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to Etoposide; GSTP1 protein promotes the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; hesperetin inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; naringenin inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; Resveratrol inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; Silymarin inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; Tocopherols inhibits the reaction [ABCC1 protein affects the export of Etoposide]; verlukast inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]

PMID:7954421 PMID:8968083 PMID:9334814 PMID:10348353 PMID:10856430 More...

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 2

affects transport
multiple interactions

ABCC2 protein affects the transport of Etoposide
Probenecid promotes the reaction [ABCC2 protein affects the transport of Etoposide]

PMID:15751272 PMID:15849751

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

decreases response to substance

ABCC3 protein results in decreased susceptibility to Etoposide

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily G member 2

multiple interactions

[ERBB2 results in increased expression of ABCG2] which results in decreased susceptibility to Etoposide; ABCG2 mutant form inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide]

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

abhydrolase domain containing 4, N-acyl phospholipase B

increases expression

Etoposide results in increased expression of ABHD4 mRNA

NCBI chr15:27,697,384...27,716,013
Ensembl chr15:27,704,113...27,716,966

G

actin-binding Rho activating protein

increases expression

Etoposide results in increased expression of ABRA mRNA

NCBI chr 7:72,970,187...72,974,255
Ensembl chr 7:72,970,186...72,974,255

G

acyl-CoA dehydrogenase medium chain

affects response to substance

ACADM protein affects the susceptibility to Etoposide

NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147

G

angiotensin converting enzyme 2

increases expression
decreases expression

Etoposide results in increased expression of ACE2 mRNA
Etoposide results in decreased expression of ACE2 mRNA

PMID:29397400 PMID:32808185

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

aconitase 1

increases expression

Etoposide results in increased expression of ACO1 mRNA

NCBI chr 5:55,259,841...55,315,872
Ensembl chr 5:55,259,827...55,316,391

G

acyl-CoA synthetase long-chain family member 3

affects response to substance

ACSL3 protein affects the susceptibility to Etoposide

NCBI chr 9:80,115,164...80,164,636
Ensembl chr 9:80,115,112...80,164,627

G

actin, alpha 1, skeletal muscle

decreases expression

Etoposide results in decreased expression of ACTA1 mRNA

NCBI chr19:51,883,709...51,886,735
Ensembl chr19:51,883,715...51,886,742

G

agrin

increases expression

Etoposide results in increased expression of AGRN mRNA

NCBI chr 5:166,749,306...166,782,212
Ensembl chr 5:166,749,310...166,786,003

G

adenosylhomocysteinase-like 1

affects response to substance

AHCYL1 protein affects the susceptibility to Etoposide

NCBI chr 2:195,294,149...195,328,586
Ensembl chr 2:195,294,153...195,345,815

G

Abelson helper integration site 1

increases expression

Etoposide results in increased expression of AHI1 protein alternative form

NCBI chr 1:15,762,485...15,891,213
Ensembl chr 1:15,762,462...15,891,041

G

A-kinase anchoring protein 12

affects response to substance

AKAP12 protein affects the susceptibility to Etoposide

NCBI chr 1:40,730,123...40,819,863
Ensembl chr 1:40,730,123...40,819,886

G

AKT serine/threonine kinase 1

increases response to substance
increases phosphorylation
multiple interactions

AKT1 protein modified form results in increased susceptibility to Etoposide
Etoposide results in increased phosphorylation of AKT1 protein
Etoposide results in increased phosphorylation of and results in increased activity of AKT1 protein; NFKB1 protein affects the reaction [Etoposide results in increased phosphorylation of AKT1 protein]; pepstatin inhibits the reaction [AKT1 protein modified form results in increased susceptibility to Etoposide]; PTEN protein inhibits the reaction [Etoposide results in increased phosphorylation of and results in increased activity of AKT1 protein]

PMID:17699715 PMID:17935137 PMID:23396362 PMID:27769712

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

aminolevulinate dehydratase

multiple interactions

[Cyclophosphamide co-treated with Carmustine co-treated with Etoposide] results in decreased activity of ALAD protein

NCBI chr 5:75,961,993...75,972,334
Ensembl chr 5:75,961,993...75,972,474

G

5'-aminolevulinate synthase 1

increases expression

Etoposide results in increased expression of ALAS1 mRNA

NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917

G

aldehyde dehydrogenase 1 family, member A1

increases expression
multiple interactions

Etoposide results in increased expression of ALDH1A1 mRNA; Etoposide results in increased expression of ALDH1A1 protein
FTL protein affects the reaction [Etoposide results in increased expression of ALDH1A1 protein]

NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961

G

aldehyde dehydrogenase 3 family, member A1

affects response to substance

ALDH3A1 protein affects the susceptibility to Etoposide

NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681

G

aldolase, fructose-bisphosphate C

affects response to substance
multiple interactions

ALDOC protein affects the susceptibility to Etoposide
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of ALDOC protein

PMID:16217747 PMID:29733421

NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066

G

alkaline phosphatase, germ cell

affects response to substance

ALPG protein affects the susceptibility to Etoposide

NCBI chr 9:87,748,721...87,761,500
Ensembl chr 9:87,753,648...87,757,836

G

alkaline phosphatase, placental

affects response to substance

ALPP protein affects the susceptibility to Etoposide

NCBI chr 9:87,765,846...87,768,606
Ensembl chr 9:87,765,860...87,768,606

G

ankyrin 1

increases expression

Etoposide results in increased expression of ANK1 mRNA

NCBI chr16:68,876,294...69,054,963
Ensembl chr16:68,877,504...69,054,759

G

ankyrin repeat domain 10

decreases expression

Etoposide results in decreased expression of ANKRD10 mRNA

NCBI chr16:77,866,489...77,889,745
Ensembl chr16:77,864,261...77,889,745

G

ankyrin repeat domain 27

decreases expression

Etoposide results in decreased expression of ANKRD27 mRNA

NCBI chr 1:88,251,216...88,303,615
Ensembl chr 1:88,251,226...88,303,615

G

ankyrin repeat domain 28

affects response to substance

ANKRD28 protein affects the susceptibility to Etoposide

NCBI chr16:6,918,487...7,050,244
Ensembl chr16:6,914,336...7,050,249

G

annexin A4

increases expression

Etoposide results in increased expression of ANXA4 mRNA

NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161

G

annexin A7

multiple interactions

[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of ANXA7 protein

NCBI chr15:3,821,798...3,849,659
Ensembl chr15:3,821,845...3,849,385

G

apoptotic peptidase activating factor 1

increases expression

Etoposide results in increased expression of APAF1 mRNA

NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540

G

apurinic/apyrimidinic endodeoxyribonuclease 1

decreases response to substance

APEX1 protein results in decreased susceptibility to Etoposide

NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785

G

amyloid beta precursor like protein 1

decreases expression

Etoposide results in decreased expression of APLP1 mRNA

NCBI chr 1:85,696,880...85,707,215
Ensembl chr 1:85,696,882...85,707,155

G

aquaporin 1

decreases expression

Etoposide results in decreased expression of AQP1 mRNA

NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690

G

androgen receptor

multiple interactions
increases degradation

calpain inhibitor 2 inhibits the reaction [Etoposide results in increased degradation of AR protein]; CAST inhibits the reaction [Etoposide results in increased degradation of AR protein]; Etoposide inhibits the reaction [Androgens results in increased activity of AR protein]; Etoposide inhibits the reaction [Metribolone results in increased activity of AR protein]

PMID:18726991 PMID:28377212 PMID:30818834

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

amphiregulin

increases expression
decreases expression

Etoposide results in increased expression of AREG mRNA; Etoposide results in increased expression of AREG protein
Etoposide results in decreased expression of AREG mRNA

PMID:15228094 PMID:25270620

NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535

G

arginase 2

decreases expression

Etoposide results in decreased expression of ARG2 mRNA

NCBI chr 6:97,936,002...97,961,379
Ensembl chr 6:97,936,002...97,961,378

G

Rho GDP dissociation inhibitor beta

increases expression

Etoposide results in increased expression of ARHGDIB mRNA

NCBI chr 4:169,822,951...169,841,884
Ensembl chr 4:169,822,952...169,841,658

G

ariadne RBR E3 ubiquitin protein ligase 1

increases response to substance

ARIH1 mutant form results in increased susceptibility to Etoposide

NCBI chr 8:59,777,378...59,879,762
Ensembl chr 8:59,777,379...59,880,245

G

ADP-ribosylation factor like GTPase 6 interacting protein 5

increases response to substance
decreases expression

ARL6IP5 protein results in increased susceptibility to Etoposide
Etoposide results in decreased expression of ARL6IP5

NCBI chr 4:129,810,650...129,838,628
Ensembl chr 4:129,810,645...129,838,608

G

aryl hydrocarbon receptor nuclear translocator

multiple interactions

ARNT protein affects the reaction [Etoposide results in increased expression of FTL protein]

NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580

G

arylsulfatase A

decreases expression

Etoposide results in decreased expression of ARSA mRNA

NCBI chr 7:120,542,788...120,547,577
Ensembl chr 7:120,543,362...120,548,783

G

N-acylsphingosine amidohydrolase 1

affects response to substance

ASAH1 protein affects the susceptibility to Etoposide

NCBI chr16:50,966,404...50,997,827
Ensembl chr16:50,966,229...51,008,233

G

activating transcription factor 2

multiple interactions

Etoposide results in increased phosphorylation of and results in increased activity of ATF2 protein

NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236

G

activating transcription factor 4

decreases expression

Etoposide results in decreased expression of ATF4 mRNA

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

ATM serine/threonine kinase

multiple interactions
increases phosphorylation

Etoposide results in increased phosphorylation of and results in increased activity of ATM protein
Etoposide results in increased phosphorylation of ATM protein
Etoposide results in increased phosphorylation of and affects the localization of ATM protein; pifithrin inhibits the reaction [Etoposide results in increased phosphorylation of and affects the localization of ATM protein]

PMID:22242153 PMID:26259609 PMID:37451322

NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437

G

ATPase 13A4

decreases expression

Etoposide results in decreased expression of ATP13A4 mRNA

NCBI chr11:71,222,196...71,359,933
Ensembl chr11:71,226,161...71,359,933

G

ATPase Na+/K+ transporting subunit alpha 1

affects response to substance

ATP1A1 protein affects the susceptibility to Etoposide

NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837

G

ATPase Na+/K+ transporting subunit alpha 2

decreases expression

Etoposide results in decreased expression of ATP1A2 mRNA

NCBI chr13:84,729,597...84,754,544
Ensembl chr13:84,729,601...84,754,544

G

ATPase Na+/K+ transporting family member beta 4

increases expression

Etoposide results in increased expression of ATP1B4 mRNA

NCBI chr X:117,087,284...117,108,023
Ensembl chr X:117,057,423...117,108,020

G

ATP synthase membrane subunit e

multiple interactions

[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in increased expression of ATP5ME protein

NCBI chr14:1,319,868...1,320,996
Ensembl chr14:1,319,868...1,321,013

G

ATP synthase peripheral stalk subunit OSCP

decreases expression

Etoposide results in decreased expression of ATP5PO protein

NCBI chr11:31,165,218...31,171,530
Ensembl chr11:31,165,217...31,171,592

G

ATPase H+ transporting V0 subunit a4

affects response to substance

ATP6V0A4 protein affects the susceptibility to Etoposide

NCBI chr 4:66,760,163...66,842,126
Ensembl chr 4:66,760,159...66,842,110

G

ATPase H+ transporting V1 subunit A

multiple interactions
decreases expression

[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of ATP6V1A protein
Etoposide results in decreased expression of ATP6V1A protein

NCBI chr11:56,561,444...56,614,694
Ensembl chr11:56,560,974...56,614,694

G

ATPase copper transporting alpha

decreases response to substance

ATP7A protein results in decreased susceptibility to Etoposide

NCBI chr X:71,094,144...71,201,550
Ensembl chr X:71,094,202...71,198,354

G

ATR serine/threonine kinase

increases phosphorylation

Etoposide results in increased phosphorylation of ATR protein

NCBI chr 8:96,426,704...96,524,152
Ensembl chr 8:96,426,724...96,524,136

G

ataxin 1

decreases expression

Etoposide results in decreased expression of ATXN1 mRNA

NCBI chr17:18,737,491...19,142,360
Ensembl chr17:18,737,533...19,142,360

G

aurora kinase A

decreases expression

Etoposide results in decreased expression of AURKA mRNA

NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390

G

arginine vasopressin-induced 1

affects response to substance

AVPI1 protein affects the susceptibility to Etoposide

NCBI chr 1:240,930,236...240,936,154
Ensembl chr 1:240,930,236...240,936,154

G

arginine vasopressin receptor 1A

increases expression

Etoposide results in increased expression of AVPR1A mRNA

NCBI chr 7:58,114,306...58,118,230
Ensembl chr 7:58,114,284...58,122,215

G

Axl receptor tyrosine kinase

increases expression

Etoposide results in increased expression of AXL mRNA

NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265

G

beta-secretase 2

affects response to substance

BACE2 protein affects the susceptibility to Etoposide

NCBI chr11:36,707,447...36,789,550
Ensembl chr11:36,707,458...36,789,546

G

BAG cochaperone 2

affects response to substance

BAG2 protein affects the susceptibility to Etoposide

NCBI chr 9:35,970,033...35,980,677
Ensembl chr 9:35,970,033...35,980,721

G

BCL2-antagonist/killer 1

increases activity
increases response to substance
affects response to substance
multiple interactions
affects expression

Etoposide results in increased activity of BAK1 protein
BAK1 protein results in increased susceptibility to Etoposide
BAK1 protein affects the susceptibility to Etoposide
nimesulide inhibits the reaction [Etoposide results in increased activity of BAK1 protein]
Etoposide affects the expression of BAK1 protein

PMID:15215046 PMID:16077961 PMID:17688235 PMID:21745461

NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264

G

BMP and activin membrane-bound inhibitor

affects response to substance

BAMBI protein affects the susceptibility to Etoposide

NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression
decreases folding
affects response to substance

[ABT-737 co-treated with Etoposide] affects the folding of and results in increased activity of BAX protein; [Cisplatin co-treated with Etoposide] affects the localization of BAX protein; [Doxorubicin co-treated with Vincristine co-treated with Etoposide co-treated with Mitotane] results in decreased expression of BAX protein; [IL4 protein co-treated with VCAM1 protein] inhibits the reaction [Etoposide results in decreased folding of BAX protein]; [RASSF1 co-treated with Etoposide] affects the folding of and results in increased activity of BAX protein; [trigonelline co-treated with Etoposide] results in increased expression of BAX protein; [VCAM1 protein co-treated with IL4 protein] inhibits the reaction [Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]]; Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]; Etoposide results in increased activity of and affects the localization of BAX protein; Etoposide results in increased cleavage of and results in increased expression of BAX protein; Nicotine inhibits the reaction [[Cisplatin co-treated with Etoposide] affects the localization of BAX protein]; nimesulide inhibits the reaction [Etoposide results in increased activity of and affects the localization of BAX protein]
Etoposide results in increased expression of BAX mRNA; Etoposide results in increased expression of BAX protein
BAX protein affects the susceptibility to Etoposide

PMID:9815696 PMID:10620629 PMID:15131059 PMID:16077961 PMID:16120219 More...

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

Bcl-2 binding component 3

increases expression
multiple interactions
affects response to substance

Etoposide results in increased expression of BBC3 mRNA; Etoposide results in increased expression of BBC3 protein
entinostat promotes the reaction [Etoposide results in increased expression of BBC3 protein]; Etoposide promotes the reaction [entinostat results in increased expression of BBC3 protein]; Etoposide promotes the reaction [trichostatin A results in increased expression of BBC3 protein]; Etoposide promotes the reaction [UF010 compound results in increased expression of BBC3 protein]; TP53 protein modified form inhibits the reaction [Etoposide results in increased expression of BBC3 protein]; trichostatin A promotes the reaction [Etoposide results in increased expression of BBC3 protein]; UF010 compound promotes the reaction [Etoposide results in increased expression of BBC3 protein]
BBC3 protein affects the susceptibility to Etoposide

PMID:20477944 PMID:21801448 PMID:25699604 PMID:37956312

NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509

G

BCL2, apoptosis regulator

multiple interactions
decreases expression

[Doxorubicin co-treated with Vincristine co-treated with Etoposide co-treated with Mitotane] results in decreased expression of BCL2 protein; [Etoposide co-treated with Ciprofloxacin] results in decreased expression of BCL2 protein; [trigonelline co-treated with Etoposide] results in decreased expression of BCL2 protein; BCL2 protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; BCL2 protein inhibits the reaction [Etoposide results in increased degradation of PARP1 protein]; BCL2 protein results in decreased susceptibility to [Cisplatin co-treated with Etoposide]
Etoposide results in decreased expression of BCL2 mRNA; Etoposide results in decreased expression of BCL2 protein
[G(M3) Ganglioside results in increased expression of BCL2 protein] which results in decreased susceptibility to Etoposide; BCL2 protein affects the reaction [[Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein]; Lithium Chloride inhibits the reaction [Etoposide results in decreased expression of BCL2 mRNA]; Lithium Chloride inhibits the reaction [Etoposide results in decreased expression of BCL2 protein]

PMID:8840993 PMID:9815696 PMID:12063570 PMID:15917659 PMID:16571667 More...

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

multiple interactions
affects expression
decreases response to substance

[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [VCAM1 protein co-treated with IL4 protein] inhibits the reaction [Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]]; BCL2L1 protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; BCL2L1 protein inhibits the reaction [Etoposide results in increased degradation of PARP1 protein]; BCL2L1 protein results in decreased susceptibility to [Cisplatin co-treated with Etoposide]; Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]
Etoposide affects the expression of BCL2L1 protein
BCL2L1 protein results in decreased susceptibility to Etoposide

PMID:8840993 PMID:10620629 PMID:11468182 PMID:15215046 PMID:15917659 More...

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

Bcl2-like 2

decreases response to substance

BCL2L2 results in decreased susceptibility to Etoposide

NCBI chr15:28,346,449...28,361,627
Ensembl chr15:28,356,807...28,361,624

G

BCL6B, transcription repressor

multiple interactions

[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of BCL6B mRNA

NCBI chr10:54,940,908...54,947,022
Ensembl chr10:54,940,909...54,945,974

G

brain-derived neurotrophic factor

increases expression
multiple interactions

Etoposide results in increased expression of BDNF mRNA
HIPK2 mutant form inhibits the reaction [Etoposide results in increased expression of BDNF mRNA]

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

BH3 interacting domain death agonist

multiple interactions
increases expression
increases cleavage

CASP9 mutant form inhibits the reaction [Etoposide results in increased cleavage of BID protein]; Estradiol inhibits the reaction [Etoposide results in increased expression of BID mRNA]

PMID:19426747 PMID:21801448

NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720

G

BCL2-interacting killer

increases response to substance

BIK protein results in increased susceptibility to Etoposide

NCBI chr 7:114,672,277...114,691,296
Ensembl chr 7:114,672,277...114,691,296

G

bridging integrator 1

increases response to substance

BIN1 protein results in increased susceptibility to Etoposide

NCBI chr18:24,009,731...24,067,267
Ensembl chr18:24,009,653...24,067,263

G

bridging integrator 3

affects response to substance

BIN3 protein affects the susceptibility to Etoposide

NCBI chr15:45,173,725...45,212,607
Ensembl chr15:45,173,732...45,212,604

G

baculoviral IAP repeat-containing 2

affects response to substance
decreases response to substance
increases expression

BIRC2 protein affects the susceptibility to Etoposide
BIRC2 protein results in decreased susceptibility to Etoposide
Etoposide results in increased expression of BIRC2 mRNA

PMID:10815900 PMID:14970392 PMID:15050749 PMID:16217747

NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732

G

baculoviral IAP repeat-containing 3

decreases response to substance
decreases expression
multiple interactions

BIRC3 protein results in decreased susceptibility to Etoposide
Etoposide results in decreased expression of BIRC3 mRNA
[Etoposide co-treated with KN 62] results in decreased expression of BIRC3 protein

PMID:14666661 PMID:15050749 PMID:16120219

NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802

G

baculoviral IAP repeat-containing 5

multiple interactions
decreases response to substance
increases expression

[FOXO3 protein results in decreased expression of BIRC5 protein] which results in increased susceptibility to Etoposide; BIRC5 protein inhibits the reaction [FOXO3 protein results in increased susceptibility to Etoposide]; BIRC5 protein results in decreased susceptibility to [Cisplatin co-treated with Etoposide]; Estradiol inhibits the reaction [Etoposide results in increased expression of BIRC5 mRNA]
BIRC5 protein results in decreased susceptibility to Etoposide

PMID:15917659 PMID:16322251 PMID:16364925 PMID:16382892 PMID:19211844 More...

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

baculoviral IAP repeat-containing 7

decreases response to substance

BIRC7 protein results in decreased susceptibility to Etoposide

NCBI chr 3:168,047,824...168,052,606
Ensembl chr 3:168,047,824...168,052,606

G

BLM RecQ like helicase

decreases expression

Etoposide results in decreased expression of BLM mRNA

NCBI chr 1:134,409,832...134,496,073
Ensembl chr 1:134,409,857...134,484,312

G

bone morphogenetic protein 6

multiple interactions

Etoposide inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]

NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365

G

BRCA1, DNA repair associated

multiple interactions
increases expression
decreases expression

BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of CDK2 protein]; BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of RAD52 protein]; BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of RAD54L protein]; BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of XRCC2 protein]; BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of XRCC3 protein]; BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of XRCC4 protein]; pifithrin inhibits the reaction [Etoposide results in increased expression of and affects the localization of BRCA1 protein]
Etoposide results in increased expression of BRCA1 protein
Etoposide results in decreased expression of BRCA1 mRNA

PMID:15607317 PMID:16417649 PMID:26259609

NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304

G

BSCL2 lipid droplet biogenesis associated, seipin

increases expression

Etoposide results in increased expression of BSCL2 mRNA

PMID:22003191 PMID:25270620

NCBI chr 1:205,731,828...205,743,430
Ensembl chr 1:205,733,872...205,743,421

G

BTG anti-proliferation factor 2

multiple interactions
increases expression

TRP53 protein affects the reaction [Etoposide results in increased expression of BTG2 mRNA]
TP53 promotes the reaction [Etoposide results in increased expression of BTG2 protein]
Etoposide results in increased expression of BTG2 mRNA; Etoposide results in increased expression of BTG2 protein

PMID:21382384 PMID:22003191 PMID:24211769 PMID:27358234

NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628

G

BTG anti-proliferation factor 3

decreases expression

Etoposide results in decreased expression of BTG3 mRNA

NCBI chr11:17,030,156...17,046,069
Ensembl chr11:17,030,160...17,046,170

G

BUB1 mitotic checkpoint serine/threonine kinase

decreases expression

Etoposide results in decreased expression of BUB1 mRNA

NCBI chr 3:115,020,254...115,051,650
Ensembl chr 3:115,020,254...115,051,650

G

BUB1 mitotic checkpoint serine/threonine kinase B

decreases expression

Etoposide results in decreased expression of BUB1B mRNA

NCBI chr 3:105,563,089...105,615,547
Ensembl chr 3:105,563,138...105,615,547

G

similar to human chromosome 4 open reading frame 19

affects response to substance

C4ORF19 protein affects the susceptibility to Etoposide

NCBI chr14:44,387,386...44,478,344
Ensembl chr14:44,387,393...44,478,041

G

complement C1q binding protein

decreases response to substance

C1QBP protein results in decreased susceptibility to Etoposide

NCBI chr10:55,699,954...55,704,605
Ensembl chr10:55,699,954...55,704,649

G

similar to human chromosome 5 open reading frame 22

affects response to substance

C5ORF22 protein affects the susceptibility to Etoposide

NCBI chr 2:61,848,790...61,864,762
Ensembl chr 2:61,849,363...61,864,738

G

calcium binding protein 39

decreases expression

Etoposide results in decreased expression of CAB39 mRNA

NCBI chr 9:86,463,095...86,524,545
Ensembl chr 9:86,463,095...86,524,544

G

calcium dependent secretion activator 2

affects response to substance

CADPS2 protein affects the susceptibility to Etoposide

NCBI chr 4:51,780,415...52,309,641
Ensembl chr 4:51,781,053...52,309,829

G

calcitonin-related polypeptide alpha

multiple interactions
decreases response to substance

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [CALCA protein results in decreased susceptibility to Etoposide]

NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105

G

calmodulin 1

increases expression

Etoposide results in increased expression of CALM1 mRNA

NCBI chr 6:119,487,691...119,495,759
Ensembl chr 6:119,487,621...119,498,227

G

caspase recruitment domain family, member 10

multiple interactions
increases expression

Estradiol inhibits the reaction [Etoposide results in increased expression of CARD10 mRNA]

NCBI chr 7:110,330,460...110,371,551
Ensembl chr 7:110,330,408...110,359,224

G

caspase 2

increases expression
increases splicing

Etoposide results in increased expression of CASP2 mRNA alternative form
Etoposide results in increased splicing of CASP2 mRNA

NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379

G

caspase 3

affects expression
increases cleavage
multiple interactions
increases activity
increases expression

Etoposide affects the expression of CASP3 protein
Etoposide results in increased cleavage of CASP3 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; 3',4'-dihydroxyflavone analog inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of CASP3 protein]; [Etoposide co-treated with Mifepristone] results in increased activity of CASP3 protein; [RASSF1 co-treated with Etoposide] results in increased cleavage of CASP3 protein; [STAT1 protein results in increased activity of CASP3 protein] which results in increased susceptibility to Etoposide; [trigonelline co-treated with Etoposide] results in increased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; Aspirin inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; BCL2 protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; BCL2L1 protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; CASP8 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; CD40LG protein inhibits the reaction [Etoposide promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]]; CDKN1A mutant form inhibits the reaction [Aspirin inhibits the reaction [Etoposide results in increased activity of CASP3 protein]]; Dehydroascorbic Acid promotes the reaction [Etoposide results in increased activity of CASP3 protein]; Etoposide promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]; Etoposide promotes the reaction [Gold results in increased activity of CASP3 protein]; Etoposide promotes the reaction [Nanotubes, Carbon results in increased activity of CASP3 protein]; Etoposide promotes the reaction [Silver results in increased activity of CASP3 protein]; Etoposide results in increased cleavage of and results in increased activity of CASP3 protein; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; nimesulide inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; Oxygen deficiency inhibits the reaction [Etoposide results in increased expression of CASP3 protein]; palbociclib inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; pifithrin promotes the reaction [Etoposide results in increased activity of CASP3 protein]; pifithrin promotes the reaction [Etoposide results in increased cleavage of CASP3 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; TMSB4X protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; Wortmannin promotes the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP3 protein]
Etoposide results in increased expression of CASP3 protein; Etoposide results in increased expression of CASP3 protein modified form
[Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein; Etoposide results in increased activity of CASP3 protein
2-tert-butylhydroquinone inhibits the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP3 protein]; BCL2 protein affects the reaction [[Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein]; Etoposide results in increased cleavage of and results in increased activity of CASP3 protein; HIPK2 gene mutant form promotes the reaction [Etoposide results in increased activity of CASP3 protein]; Metoclopramide inhibits the reaction [Etoposide results in increased activity of CASP3 protein]

PMID:8840993 PMID:10759716 PMID:12871656 PMID:15215046 PMID:15924153 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 7

multiple interactions
increases activity

[STAT1 protein results in increased activity of CASP7 protein] which results in increased susceptibility to Etoposide; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Etoposide results in increased activity of CASP7 protein]; palbociclib inhibits the reaction [Etoposide results in increased activity of CASP7 protein]; pifithrin promotes the reaction [Etoposide results in increased activity of CASP7 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased activity of CASP7 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased activity of CASP7 protein]
2-tert-butylhydroquinone inhibits the reaction [Etoposide results in increased activity of CASP7 protein]

PMID:18056177 PMID:18649362 PMID:20299546 PMID:21801448 PMID:22275372 More...

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

caspase 8

multiple interactions
increases response to substance
increases cleavage
increases activity
decreases response to substance

3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione inhibits the reaction [Etoposide results in increased activity of CASP8 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of CASP3 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of PARP1 protein]; [CASP8 co-treated with TP53] inhibits the reaction [CASP8 protein mutant form results in decreased susceptibility to Etoposide]; acetyl-leucyl-glutamyl-histidyl-aspartal inhibits the reaction [Etoposide results in increased activity of CASP8 protein]; CASP8 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; CASP8 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP9 protein]; Etoposide results in increased cleavage of and results in increased activity of CASP8 protein; Etoposide results in increased expression of and results in increased cleavage of CASP8 protein; Lithium inhibits the reaction [Etoposide results in increased activity of CASP8 protein]; nimesulide inhibits the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP8 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP8 protein]
CASP8 protein results in increased susceptibility to Etoposide

PMID:15475000 PMID:21745461 PMID:21801448 PMID:22010212

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions
increases cleavage
increases activity
affects expression

[CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]; [Cisplatin co-treated with Etoposide] results in increased activity of CASP9 protein; CASP8 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP9 protein]; CASP9 mutant form inhibits the reaction [Etoposide results in increased cleavage of BID protein]; Etoposide results in increased cleavage of and results in increased activity of CASP9 protein; HTATIP2 protein promotes the reaction [Etoposide results in increased activity of CASP9 protein]; MYC protein promotes the reaction [Etoposide results in increased cleavage of CASP9 protein]; Nicotine inhibits the reaction [[Cisplatin co-treated with Etoposide] results in increased activity of CASP9 protein]; nimesulide inhibits the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]; TMSB4X protein inhibits the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]; Wortmannin promotes the reaction [Etoposide results in increased cleavage of CASP9 protein]
Etoposide affects the expression of CASP9 protein

PMID:12925536 PMID:15215046 PMID:16364925 PMID:16799960 PMID:17935137 More...

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

calsequestrin 2

decreases expression

Etoposide results in decreased expression of CASQ2 mRNA

NCBI chr 2:189,526,003...189,582,276
Ensembl chr 2:189,525,960...189,582,267

G

calpastatin

multiple interactions

CAST inhibits the reaction [Etoposide results in increased degradation of AR protein]

NCBI chr 2:3,973,112...4,082,658
Ensembl chr 2:3,973,112...4,082,659

G

catalase

increases response to substance
multiple interactions
increases activity

CAT results in increased susceptibility to Etoposide
EPO protein inhibits the reaction [Etoposide results in increased activity of CAT protein]

PMID:21689642 PMID:25451571 PMID:29069929

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

coiled-coil domain containing 51

decreases expression

Etoposide results in decreased expression of CCDC51 mRNA

NCBI chr 8:109,722,595...109,741,478
Ensembl chr 8:109,722,557...109,741,472

G

coiled-coil domain containing 6

increases response to substance
decreases response to substance

CCDC6 results in increased susceptibility to Etoposide
CCDC6 results in decreased susceptibility to Etoposide

PMID:22363533 PMID:22655027

NCBI chr20:18,432,177...18,528,186
Ensembl chr20:18,433,695...18,528,658

G

C-C motif chemokine ligand 3

increases expression

Etoposide results in increased expression of CCL3 protein

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

cellular communication network factor 2

increases expression

Etoposide results in increased expression of CCN2 mRNA

NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734

G

cyclin A2

multiple interactions
decreases expression

Etoposide affects the expression of and affects the localization of CCNA2 protein
Etoposide results in decreased expression of CCNA2 mRNA; Etoposide results in decreased expression of CCNA2 protein

PMID:16120219 PMID:17390037

NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577

G

cyclin B1

decreases expression

Etoposide results in decreased expression of CCNB1 mRNA; Etoposide results in decreased expression of CCNB1 protein

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cyclin D1

increases expression

Etoposide results in increased expression of CCND1 mRNA

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin G1

increases expression

Etoposide results in increased expression of CCNG1 mRNA

NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641

G

cyclin G2

increases expression

Etoposide results in increased expression of CCNG2 mRNA

NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830

G

copper chaperone for superoxide dismutase

increases expression

Etoposide results in increased expression of CCS mRNA

NCBI chr 1:202,113,792...202,134,931
Ensembl chr 1:202,113,804...202,134,915

G

chaperonin containing TCP1 subunit 8

multiple interactions

[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of CCT8 protein

NCBI chr11:26,710,370...26,722,079
Ensembl chr11:26,710,370...26,722,079

G

CD274 molecule

increases expression

Etoposide results in increased expression of CD274 protein

NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450

G

CD40 ligand

multiple interactions
decreases response to substance

CD40LG protein inhibits the reaction [Etoposide promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]]
CD40LG protein results in decreased susceptibility to Etoposide

NCBI chr X:135,127,052...135,138,768
Ensembl chr X:135,126,969...135,138,306

G

CD44 molecule

affects response to substance
multiple interactions

CD44 protein affects the susceptibility to Etoposide
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide]

PMID:15215046 PMID:19047049

NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620

G

CD55 molecule (Cromer blood group)

affects response to substance

CD55 protein affects the susceptibility to Etoposide

NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831

G

CD59b molecule

multiple interactions

[Cisplatin co-treated with Etoposide] results in decreased expression of CD59 protein

NCBI chr 3:90,459,085...90,477,571
Ensembl chr 3:90,459,162...90,478,847

G

cell division cycle 25A

decreases expression

Etoposide results in decreased expression of CDC25A mRNA

NCBI chr 8:109,864,356...109,882,734
Ensembl chr 8:109,864,478...109,882,701

G

cell division cycle 25C

decreases expression

Etoposide results in decreased expression of CDC25C mRNA

NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185

G

CDC42 binding protein kinase gamma

increases expression

Etoposide results in increased expression of CDC42BPG mRNA

NCBI chr 1:203,608,339...203,628,502
Ensembl chr 1:203,608,574...203,628,502

G

cell division cycle 45

decreases expression

Etoposide results in decreased expression of CDC45 mRNA

NCBI chr11:82,185,427...82,210,630
Ensembl chr11:82,185,473...82,210,619

G

cell division cycle 6

decreases expression

Etoposide results in decreased expression of CDC6 mRNA

NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011

G

cyclin dependent kinase 2

multiple interactions
increases expression
affects response to substance

BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of CDK2 protein]; CDK2 affects the reaction [Etoposide results in increased phosphorylation of TPI1 protein]
CDK2 protein affects the susceptibility to Etoposide

PMID:16217747 PMID:16417649 PMID:20149834

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase inhibitor 1A

multiple interactions
increases expression

[Etoposide results in increased susceptibility to Benzo(a)pyrene] which results in increased expression of CDKN1A protein; [RASSF1 co-treated with Etoposide] results in increased expression of CDKN1A protein; CDKN1A mutant form inhibits the reaction [Aspirin inhibits the reaction [Etoposide results in increased activity of CASP3 protein]]; CDKN1A protein affects the reaction [Etoposide results in decreased expression of UBE2C protein]; entinostat promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; Etoposide promotes the reaction [entinostat results in increased expression of CDKN1A protein]; Etoposide promotes the reaction [trichostatin A results in increased expression of CDKN1A protein]; Etoposide promotes the reaction [UF010 compound results in increased expression of CDKN1A protein]; KEAP1 protein affects the reaction [Etoposide results in increased expression of CDKN1A protein]; resveratrol inhibits the reaction [Etoposide results in increased expression of CDKN1A mRNA]; TP53 affects the reaction [Etoposide results in increased expression of CDKN1A mRNA]; TP53 promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; TP53 protein promotes the reaction [[Etoposide results in increased susceptibility to Benzo(a)pyrene] which results in increased expression of CDKN1A protein]; TP53 protein promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; trichostatin A promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; UF010 compound promotes the reaction [Etoposide results in increased expression of CDKN1A protein]
Etoposide results in increased expression of CDKN1A mRNA; Etoposide results in increased expression of CDKN1A protein
[CDKN2A gene mutant form results in increased expression of CDKN2A protein alternative form] inhibits the reaction [Etoposide results in increased expression of CDKN1A protein]; TRP53 affects the reaction [Etoposide results in increased expression of CDKN1A mRNA]
cordycepin inhibits the reaction [Etoposide results in increased expression of CDKN1A mRNA]; Etoposide promotes the reaction [Niacin deficiency results in increased expression of CDKN1A protein]; mithramycin A inhibits the reaction [Etoposide results in increased expression of CDKN1A mRNA]; salubrinal inhibits the reaction [Etoposide results in increased expression of CDKN1A mRNA]

PMID:14601052 PMID:16120219 PMID:16882877 PMID:17516866 PMID:21212465 More...

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

increases expression
multiple interactions

Etoposide results in increased expression of CDKN1B protein
wortmannin promotes the reaction [Etoposide results in increased expression of CDKN1B protein]

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

cyclin-dependent kinase inhibitor 2A

increases expression
multiple interactions

Etoposide results in increased expression of CDKN2A mRNA
[CDKN2A gene mutant form results in increased expression of CDKN2A protein alternative form] inhibits the reaction [Etoposide results in increased expression of CDKN1A protein]; [CDKN2A gene mutant form results in increased expression of CDKN2A protein alternative form] inhibits the reaction [Etoposide results in increased expression of TRP53 protein]
cordycepin inhibits the reaction [Etoposide results in increased expression of CDKN2A mRNA]; mithramycin A inhibits the reaction [Etoposide results in increased expression of CDKN2A mRNA]; salubrinal inhibits the reaction [Etoposide results in increased expression of CDKN2A mRNA]

PMID:21526190 PMID:23690541

NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149

G

cyclin-dependent kinase inhibitor 3

decreases expression

Etoposide results in decreased expression of CDKN3 mRNA

NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945

G

CEA cell adhesion molecule 1

increases expression

Etoposide results in increased expression of CEACAM1 mRNA

NCBI chr 1:81,043,595...81,060,050
Ensembl chr 1:81,043,595...81,059,992

G

CCAAT/enhancer binding protein alpha

decreases expression
increases degradation

Etoposide results in decreased expression of CEBPA mRNA; Etoposide results in decreased expression of CEBPA protein
Etoposide results in increased degradation of CEBPA protein

NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412

G

CCAAT/enhancer binding protein zeta

decreases expression

Etoposide results in decreased expression of CEBPZ mRNA

NCBI chr 6:16,119,871...16,137,600
Ensembl chr 6:16,119,872...16,137,600

G

carboxyl ester lipase

increases expression

Etoposide results in increased expression of CEL mRNA

NCBI chr 3:11,883,532...11,891,035
Ensembl chr 3:11,883,532...11,891,035

G

centromere protein F

decreases expression

Etoposide results in decreased expression of CENPF mRNA

NCBI chr13:101,184,127...101,229,714
Ensembl chr13:101,184,127...101,229,669

G

cerebral endothelial cell adhesion molecule

increases expression

Etoposide results in increased expression of CERCAM mRNA

NCBI chr 3:13,118,150...13,155,960
Ensembl chr 3:13,142,107...13,155,956

G

carboxylesterase 1D

increases expression

Etoposide results in increased expression of CES1D mRNA

NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035

G

carboxylesterase 2E

increases expression

Etoposide results in increased expression of CES2E mRNA

NCBI chr19:157,447...172,822
Ensembl chr19:157,407...172,856

G

CASP8 and FADD-like apoptosis regulator

increases expression

Etoposide results in increased expression of CFLAR protein

NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034

G

cell growth regulator with EF hand domain 1

increases expression

Etoposide results in increased expression of CGREF1 mRNA

NCBI chr 6:25,431,846...25,443,853
Ensembl chr 6:25,431,799...25,443,852

G

ChaC glutathione-specific gamma-glutamylcyclotransferase 1

decreases expression

Etoposide results in decreased expression of CHAC1 mRNA

NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526

G

chromatin assembly factor 1 subunit A

decreases expression

Etoposide results in decreased expression of CHAF1A mRNA

NCBI chr 9:873,953...900,701
Ensembl chr 9:874,051...900,654

G

checkpoint kinase 1

affects response to substance
multiple interactions

CHEK1 protein affects the susceptibility to Etoposide
TP53 protein affects the reaction [CHEK1 protein affects the susceptibility to Etoposide]

NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009

G

checkpoint kinase 2

increases phosphorylation
multiple interactions

Etoposide results in increased phosphorylation of CHEK2 protein
4-fluoro-2-(4-(4-(2-hydroxypropan-2-yl)pyrrolidin-3-ylamino)-6,7-dimethoxyquinazolin-2-yl)phenol inhibits the reaction [Etoposide results in increased phosphorylation of CHEK2 protein]; pifithrin inhibits the reaction [Etoposide results in increased phosphorylation of CHEK2 protein]

PMID:21186793 PMID:22242153 PMID:26259609

NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286

G

chitinase 3 like 1

decreases response to substance

CHI3L1 results in decreased susceptibility to Etoposide

NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787

G

component of inhibitor of nuclear factor kappa B kinase complex

decreases expression

Etoposide results in decreased expression of CHUK protein

NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065

G

cytokine induced apoptosis inhibitor 1

decreases response to substance

CIAPIN1 protein results in decreased susceptibility to Etoposide

NCBI chr19:10,179,963...10,195,511
Ensembl chr19:10,180,100...10,195,503

G

creatine kinase, M-type

decreases expression

Etoposide results in decreased expression of CKM mRNA

NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720

G

creatine kinase, mitochondrial 1

affects response to substance

CKMT1B protein affects the susceptibility to Etoposide

NCBI chr 3:108,329,859...108,335,760
Ensembl chr 3:108,330,705...108,335,758

G

cytochrome c oxidase assembly factor 7

decreases expression

Etoposide results in decreased expression of COA7 mRNA

NCBI chr 5:123,069,356...123,080,942
Ensembl chr 5:123,069,371...123,080,199

G

cordon-bleu WH2 repeat protein

decreases expression

Etoposide results in decreased expression of COBL mRNA

NCBI chr14:86,828,137...87,060,682
Ensembl chr14:86,828,139...87,060,800

G

collagen type XV alpha 1 chain

affects response to substance

COL15A1 protein affects the susceptibility to Etoposide

NCBI chr 5:61,501,963...61,607,591
Ensembl chr 5:61,501,963...61,607,591

G

collagen type IV alpha 1 chain

decreases expression

Etoposide results in decreased expression of COL4A1 mRNA

NCBI chr16:78,183,533...78,294,412
Ensembl chr16:78,183,533...78,294,412

G

collagen type IX alpha 3 chain

affects response to substance

COL9A3 protein affects the susceptibility to Etoposide

NCBI chr 3:167,711,776...167,734,468
Ensembl chr 3:167,711,840...167,734,465

G

cytochrome c oxidase subunit 6A2

decreases expression

Etoposide results in decreased expression of COX6A2 mRNA

NCBI chr 1:182,788,528...182,790,746
Ensembl chr 1:182,788,528...182,789,274

G

carbamoyl-phosphate synthase 1

affects response to substance

CPS1 protein affects the susceptibility to Etoposide

NCBI chr 9:68,614,153...68,737,037
Ensembl chr 9:68,614,153...68,737,033

G

carnitine palmitoyltransferase 2

decreases expression

Etoposide results in decreased expression of CPT2 mRNA

NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095

G

cellular retinoic acid binding protein 2

increases expression

Etoposide results in increased expression of CRABP2 mRNA

NCBI chr 2:173,417,004...173,421,352
Ensembl chr 2:173,416,857...173,421,379

G

cAMP responsive element binding protein 1

multiple interactions

Etoposide results in increased expression of and results in increased phosphorylation of CREB1 protein; HIPK2 gene mutant form inhibits the reaction [Etoposide results in increased expression of and results in increased phosphorylation of CREB1 protein]

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

cAMP responsive element modulator

affects response to substance

CREM protein affects the susceptibility to Etoposide

NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989

G

cysteine-rich protein 2

increases expression

Etoposide results in increased expression of CRIP2 mRNA

NCBI chr 6:132,221,120...132,226,066
Ensembl chr 6:132,221,082...132,226,065

G

chondroitin sulfate N-acetylgalactosaminyltransferase 1

affects response to substance

CSGALNACT1 protein affects the susceptibility to Etoposide

NCBI chr16:20,995,210...21,330,586
Ensembl chr16:21,235,784...21,330,319

G

cystathionine gamma-lyase

affects response to substance

CTH protein affects the susceptibility to Etoposide

NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234

G

catenin beta 1

multiple interactions

[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide]

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

C-X-C motif chemokine ligand 12

decreases expression

Etoposide results in decreased expression of CXCL12 mRNA; Etoposide results in decreased expression of CXCL12 protein

NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168

G

cytochrome c, somatic

affects localization

Etoposide affects the localization of CYCS protein

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression
multiple interactions

Etoposide results in increased expression of CYP1A1 mRNA; Etoposide results in increased expression of CYP1A1 protein
Etoposide promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]; TP53 protein promotes the reaction [Etoposide promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]]; TP53 protein promotes the reaction [Etoposide results in increased expression of CYP1A1 protein]

PMID:29471073 PMID:31542801

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases expression

Etoposide results in increased expression of CYP1A2 mRNA

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 26, subfamily a, polypeptide 1

decreases response to substance

CYP26A1 protein results in decreased susceptibility to Etoposide

NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204

G

cytochrome P450, family 27, subfamily b, polypeptide 1

increases expression

Etoposide results in increased expression of CYP27B1 mRNA

NCBI chr 7:62,869,340...62,876,242
Ensembl chr 7:62,871,297...62,876,241

G

cytochrome P450, family 2, subfamily c, polypeptide 24

increases expression

Etoposide results in increased expression of CYP2C55 mRNA

NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238

G

cytochrome P450, family 2, subfamily C, polypeptide 6

increases expression

Etoposide results in increased expression of CYP2C29 mRNA

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily s, polypeptide 1

decreases expression

Etoposide results in decreased expression of CYP2S1 mRNA

NCBI chr 1:81,309,948...81,325,303
Ensembl chr 1:81,310,451...81,325,303

G

cytochrome P450, family 3, subfamily a, polypeptide 2

decreases methylation
increases expression
multiple interactions
affects response to substance

CYP3A4 protein results in decreased methylation of Etoposide
Etoposide results in increased expression of CYP3A4 mRNA
[Etoposide results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; Cyclosporine inhibits the reaction [CYP3A4 protein results in decreased methylation of Etoposide]; Dexamethasone inhibits the reaction [CYP3A4 protein results in decreased methylation of Etoposide]; Erythromycin inhibits the reaction [CYP3A4 protein results in decreased methylation of Etoposide]; Midazolam inhibits the reaction [CYP3A4 protein results in decreased methylation of Etoposide]
CYP3A4 gene polymorphism affects the susceptibility to Etoposide; CYP3A4 protein affects the susceptibility to Etoposide

PMID:8114683 PMID:12969965 PMID:17279585 PMID:25455453 PMID:31542801

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 9

affects response to substance
decreases methylation

CYP3A5 gene polymorphism affects the susceptibility to Etoposide
CYP3A5 protein results in decreased methylation of Etoposide

PMID:8114683 PMID:12969965

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

cell cycle regulator of NHEJ

affects localization

Etoposide affects the localization of CYREN protein alternative form

NCBI chr 4:63,547,311...63,553,394
Ensembl chr 4:63,547,335...63,551,602

G

DAB adaptor protein 2

affects response to substance

DAB2 protein affects the susceptibility to Etoposide

NCBI chr 2:55,514,692...55,567,476
Ensembl chr 2:55,514,700...55,567,476

G

death associated protein kinase 1

increases expression
multiple interactions

Etoposide results in increased expression of DAPK1 protein; Etoposide results in increased expression of DAPK1 protein modified form
DAPK1 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]; DAPK1 protein promotes the reaction [Etoposide results in increased expression of ETS1 protein]; DAPK1 protein promotes the reaction [Etoposide results in increased expression of TP53 protein modified form]; DAPK1 protein promotes the reaction [Etoposide results in increased expression of TP53 protein]

NCBI chr17:3,930,223...4,090,991
Ensembl chr17:3,930,213...4,090,991

G

DBF4-CDC7 kinase regulatory subunit

decreases expression

Etoposide results in decreased expression of DBF4 mRNA

NCBI chr 4:25,676,570...25,701,152
Ensembl chr 4:25,676,634...25,701,066

G

drebrin 1

affects response to substance

DBN1 protein affects the susceptibility to Etoposide

NCBI chr17:9,150,608...9,164,982
Ensembl chr17:9,150,659...9,164,984

G

DDB1 and CUL4 associated factor 4

increases expression

Etoposide results in increased expression of DCAF4 mRNA

NCBI chr 6:103,154,847...103,180,992
Ensembl chr 6:103,154,867...103,180,982

G

dopachrome tautomerase

affects response to substance

DCT protein affects the susceptibility to Etoposide

NCBI chr15:95,062,006...95,100,863
Ensembl chr15:95,062,003...95,100,836

G

DNA-damage-inducible transcript 4

affects response to substance

DDIT4 protein affects the susceptibility to Etoposide

NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105

G

discoidin domain receptor tyrosine kinase 1

increases expression

Etoposide results in increased expression of DDR1 mRNA

NCBI chr20:3,042,494...3,064,442
Ensembl chr20:3,044,320...3,064,468

G

desmin

decreases expression

Etoposide results in decreased expression of DES mRNA

NCBI chr 9:76,850,979...76,858,695
Ensembl chr 9:76,850,982...76,858,699

G

dickkopf WNT signaling pathway inhibitor 3

affects response to substance

DKK3 protein affects the susceptibility to Etoposide

NCBI chr 1:166,237,969...166,281,271
Ensembl chr 1:166,238,238...166,280,590

G

dystrophin

affects response to substance
decreases expression

DMD protein affects the susceptibility to Etoposide
Etoposide results in decreased expression of DMD mRNA

PMID:16217747 PMID:29397400

NCBI chr X:47,272,324...49,504,219
Ensembl chr X:47,272,331...49,504,207

G

doublesex and mab-3 related transcription factor 1

decreases expression

Etoposide results in decreased expression of DMRT1 mRNA

NCBI chr 1:223,142,859...223,241,333
Ensembl chr 1:223,142,859...223,241,333

G

DNA methyltransferase 1

decreases response to substance

DNMT1 protein results in decreased susceptibility to Etoposide

NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659

G

DNA methyltransferase 3 beta

decreases response to substance

DNMT3B protein results in decreased susceptibility to Etoposide

NCBI chr 3:142,130,588...142,169,128
Ensembl chr 3:142,130,592...142,169,124

G

dipeptidylpeptidase 7

multiple interactions

Etoposide promotes the reaction [[DPP7 protein results in increased cleavage of Dipeptides] which results in increased abundance of 4-nitroaniline]

NCBI chr 3:8,165,091...8,169,343
Ensembl chr 3:8,165,091...8,169,355

G

dihydropyrimidinase-like 2

decreases expression

Etoposide results in decreased expression of DPYSL2 protein

NCBI chr15:41,005,551...41,111,724
Ensembl chr15:41,005,551...41,111,829

G

dihydropyrimidinase-like 4

increases expression

Etoposide results in increased expression of DPYSL4 mRNA

NCBI chr 1:193,883,039...193,898,916
Ensembl chr 1:193,883,106...193,898,914

G

dual specificity phosphatase 2

affects response to substance

DUSP2 protein affects the susceptibility to Etoposide

NCBI chr 3:114,556,325...114,558,510
Ensembl chr 3:114,556,325...114,558,499

G

dual specificity phosphatase 4

affects response to substance
increases expression

DUSP4 protein affects the susceptibility to Etoposide
Etoposide results in increased expression of DUSP4 mRNA

PMID:16217747 PMID:29397400

NCBI chr16:57,376,659...57,398,161
Ensembl chr16:57,377,229...57,398,138

G

E2F transcription factor 1

multiple interactions

E2F1 protein affects the reaction [Etoposide results in increased expression of HIC1 mRNA]; Etoposide promotes the reaction [E2F1 protein binds to HIC1 promoter]

NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361

G

endothelin 1

multiple interactions

EDN1 mutant form inhibits the reaction [VEGFC protein results in decreased susceptibility to Etoposide]

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

endothelin receptor type B

decreases expression

Etoposide results in decreased expression of EDNRB mRNA

NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115

G

embryonal Fyn-associated substrate

increases expression

Etoposide results in increased expression of EFS mRNA

NCBI chr15:28,392,417...28,403,016
Ensembl chr15:28,392,187...28,401,902

G

epidermal growth factor

multiple interactions

[EGF protein results in decreased expression of TOP2A protein] which results in decreased susceptibility to Etoposide

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

EGF-like-domain, multiple 8

affects response to substance

EGFL8 protein affects the susceptibility to Etoposide

NCBI chr20:4,132,930...4,136,024
Ensembl chr20:4,133,629...4,136,018

G

epidermal growth factor receptor

decreases expression

Etoposide results in decreased expression of EGFR mRNA; Etoposide results in decreased expression of EGFR protein

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

EI24, autophagy associated transmembrane protein

increases expression

Etoposide results in increased expression of EI24 mRNA

NCBI chr 8:36,494,289...36,510,653
Ensembl chr 8:36,494,289...36,510,571

G

eukaryotic translation initiation factor 2 subunit beta

decreases expression

Etoposide results in decreased expression of EIF2S2 mRNA

NCBI chr 3:143,374,652...143,395,460
Ensembl chr 3:143,373,686...143,395,432

G

eukaryotic translation initiation factor 3, subunit A

increases response to substance

EIF3A results in increased susceptibility to Etoposide

NCBI chr 1:259,902,767...259,932,976
Ensembl chr 1:259,902,680...259,932,976

G

epithelial membrane protein 1

increases expression

Etoposide results in increased expression of EMP1 mRNA

NCBI chr 4:168,212,901...168,233,039
Ensembl chr 4:168,212,861...168,232,904

G

epithelial membrane protein 2

affects response to substance

EMP2 protein affects the susceptibility to Etoposide

NCBI chr10:5,360,073...5,394,734
Ensembl chr10:5,360,073...5,394,733

G

epithelial membrane protein 3

increases expression

Etoposide results in increased expression of EMP3 mRNA

NCBI chr 1:96,388,651...96,391,946
Ensembl chr 1:96,388,652...96,391,988

G

engrailed homeobox 2

affects response to substance

EN2 protein affects the susceptibility to Etoposide

NCBI chr 4:7,221,096...7,226,943
Ensembl chr 4:7,221,096...7,226,943

G

enolase 1

decreases expression

Etoposide results in decreased expression of ENO1 protein

NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336

G

ectonucleoside triphosphate diphosphohydrolase 2

decreases expression

Etoposide results in decreased expression of ENTPD2 mRNA

NCBI chr 3:8,213,575...8,219,094
Ensembl chr 3:8,213,663...8,226,866

G

E1A binding protein p300

multiple interactions

[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide]

NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088
Ensembl chr 7:113,106,247...113,136,088

G

erythrocyte membrane protein band 4.1-like 3

affects response to substance

EPB41L3 protein affects the susceptibility to Etoposide

NCBI chr 9:109,056,178...109,260,607
Ensembl chr 9:109,016,113...109,260,607

G

epoxide hydrolase 1

increases expression

Etoposide results in increased expression of EPHX1 mRNA

PMID:21382384 PMID:25270620

NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235

G

EPM2A interacting protein 1

increases expression

Etoposide results in increased expression of EPM2AIP1 mRNA

NCBI chr 8:111,233,871...111,241,219
Ensembl chr 8:111,233,826...111,241,871

G

erythropoietin

multiple interactions

EPO protein inhibits the reaction [Etoposide results in increased activity of CAT protein]; EPO protein results in increased susceptibility to [Organoplatinum Compounds co-treated with Etoposide]

PMID:18403296 PMID:29069929

NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946

G

erb-b2 receptor tyrosine kinase 2

multiple interactions
decreases expression
decreases response to substance
affects response to substance

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide]; [ERBB2 results in increased expression of ABCG2] which results in decreased susceptibility to Etoposide; ABCG2 mutant form inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide]; Curcumin analog inhibits the reaction [ERBB2 protein results in decreased susceptibility to Etoposide]
Etoposide results in decreased expression of ERBB2 mRNA
ERBB2 protein results in decreased susceptibility to Etoposide; ERBB2 results in decreased susceptibility to Etoposide
ERBB2 protein affects the susceptibility to Etoposide

PMID:10327070 PMID:15228094 PMID:21712253 PMID:25866362

NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078

G

erb-b2 receptor tyrosine kinase 3

affects response to substance
decreases expression

ERBB3 protein affects the susceptibility to Etoposide
Etoposide results in decreased expression of ERBB3 mRNA

PMID:15228094 PMID:16217747 PMID:29397400

NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525

G

erb-b2 receptor tyrosine kinase 4

decreases expression

Etoposide results in decreased expression of ERBB4 mRNA

NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595

G

epiregulin

increases expression

Etoposide results in increased expression of EREG mRNA

NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062

G

endogenous retrovirus group FRD member 1, envelope

affects response to substance

ERVFRD-1 protein affects the susceptibility to Etoposide

NCBI chr12:22,151,211...22,158,264
Ensembl chr12:22,151,211...22,158,264

G

estrogen receptor 1

multiple interactions

Etoposide inhibits the reaction [Estradiol results in increased activity of ESR1 protein]

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

estrogen receptor 2

increases response to substance
multiple interactions

ESR2 protein results in increased susceptibility to Etoposide
TP53 protein inhibits the reaction [ESR2 protein results in increased susceptibility to Etoposide]

NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919

G

epithelial splicing regulatory protein 1

affects response to substance

ESRP1 protein affects the susceptibility to Etoposide

NCBI chr 5:24,427,611...24,482,157
Ensembl chr 5:24,428,717...24,482,062

G

estrogen related receptor, alpha

multiple interactions

Etoposide inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]; Etoposide promotes the reaction [PPARGC1A protein results in increased activity of ESRRA protein]

NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268

G

ETS proto-oncogene 1, transcription factor

multiple interactions
increases expression

DAPK1 protein promotes the reaction [Etoposide results in increased expression of ETS1 protein]; ETS1 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]; TP53 protein promotes the reaction [Etoposide results in increased expression of ETS1 protein]

NCBI chr 8:31,045,909...31,168,010
Ensembl chr 8:31,045,945...31,168,010

G

ETS variant transcription factor 6

increases response to substance
increases mutagenesis

ETV6 gene mutant form results in increased susceptibility to Etoposide
Etoposide results in increased mutagenesis of ETV6 gene

PMID:15217836 PMID:28624474

NCBI chr 4:166,849,031...167,085,211
Ensembl chr 4:166,847,686...167,084,992

G

exocyst complex component 4

increases expression

Etoposide results in increased expression of EXOC4 mRNA

NCBI chr 4:61,807,706...62,584,316
Ensembl chr 4:61,807,761...62,585,723

G

F11 receptor

increases expression

Etoposide results in increased expression of F11R mRNA

NCBI chr13:83,873,797...83,897,388
Ensembl chr13:83,873,797...83,897,402

G

coagulation factor II (thrombin) receptor

affects response to substance

F2R protein affects the susceptibility to Etoposide

NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870

G

coagulation factor III, tissue factor

increases expression

Etoposide results in increased expression of F3 mRNA

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

fatty acid desaturase 3

increases expression

Etoposide results in increased expression of FADS3 mRNA

NCBI chr 1:206,685,667...206,702,538
Ensembl chr 1:206,685,894...206,704,769

G

family with sequence similarity 171, member A1

affects response to substance

FAM171A1 protein affects the susceptibility to Etoposide

NCBI chr17:75,024,582...75,148,348
Ensembl chr17:75,024,575...75,150,255

G

Fas cell surface death receptor

multiple interactions
increases expression

3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione inhibits the reaction [Etoposide results in increased expression of and affects the localization of FAS protein]; Etoposide results in increased expression of and affects the localization of FAS protein; Lithium inhibits the reaction [Etoposide results in increased expression of and affects the localization of FAS protein]
Etoposide results in increased expression of FAS mRNA
Etoposide results in increased expression of FAS mRNA; Etoposide results in increased expression of FAS protein

PMID:12513834 PMID:15475000 PMID:16192531 PMID:29397400

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

Fas ligand

multiple interactions
increases expression
increases activity

[linsidomine results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; [S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; [S-Nitrosoglutathione results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; [spermine nitric oxide complex results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; Nitric Oxide inhibits the reaction [Etoposide results in increased activity of FASLG promoter]
Etoposide results in increased expression of FASL mRNA

PMID:10811113 PMID:12513834

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

fatty acid synthase

increases expression

Etoposide results in increased expression of FASN mRNA

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

fibrillarin

affects localization

Etoposide analog affects the localization of FBL protein

NCBI chr 1:83,469,832...83,478,932
Ensembl chr 1:83,469,832...83,478,932

G

farnesyl diphosphate farnesyl transferase 1

affects response to substance

FDFT1 protein affects the susceptibility to Etoposide

NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287

G

ferredoxin reductase

increases expression

Etoposide results in increased expression of FDXR mRNA

NCBI chr10:100,507,863...100,516,649
Ensembl chr10:100,507,865...100,516,658

G

fibroblast growth factor 2

affects response to substance

FGF2 protein affects the susceptibility to Etoposide

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

four and a half LIM domains 1

affects response to substance

FHL1 protein affects the susceptibility to Etoposide

NCBI chr X:134,555,399...134,614,930
Ensembl chr X:134,555,479...134,614,928

G

four and a half LIM domains 2

decreases expression

Etoposide results in decreased expression of FHL2 mRNA

NCBI chr 9:45,388,979...45,462,421
Ensembl chr 9:45,388,981...45,431,192

G

filamin C

increases expression

Etoposide results in increased expression of FLNC mRNA

NCBI chr 4:58,034,088...58,061,882
Ensembl chr 4:58,034,189...58,061,844

G

Fos proto-oncogene, AP-1 transcription factor subunit

decreases response to substance
increases expression
multiple interactions

FOS protein results in decreased susceptibility to Etoposide
Etoposide results in increased expression of FOS
[Etoposide co-treated with Cyclic AMP] results in increased expression of FOS mRNA; Acetylcysteine inhibits the reaction [Etoposide results in increased expression of FOS]

PMID:10711420 PMID:18314485 PMID:23824011

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

FOS like 1, AP-1 transcription factor subunit

increases expression

Etoposide results in increased expression of FOSL1 mRNA

NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930

G

forkhead box F2

affects response to substance

FOXF2 protein affects the susceptibility to Etoposide

NCBI chr17:32,835,730...32,842,547
Ensembl chr17:32,836,777...32,842,176

G

forkhead box J2

decreases expression

Etoposide results in decreased expression of FOXJ2 mRNA

NCBI chr 4:156,047,043...156,073,540
Ensembl chr 4:156,046,969...156,073,518

G

forkhead box O1

increases phosphorylation
multiple interactions

Etoposide results in increased phosphorylation of FOXO1 protein
wortmannin inhibits the reaction [Etoposide results in increased phosphorylation of FOXO1 protein]

NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790

G

forkhead box O3

increases phosphorylation
increases response to substance
multiple interactions

Etoposide results in increased phosphorylation of FOXO3 protein
FOXO3 protein results in increased susceptibility to Etoposide
[FOXO3 protein results in decreased expression of BIRC5 protein] which results in increased susceptibility to Etoposide; BIRC5 protein inhibits the reaction [FOXO3 protein results in increased susceptibility to Etoposide]; Wortmannin inhibits the reaction [Etoposide results in increased phosphorylation of FOXO3 protein]

PMID:17935137 PMID:19211844

NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561

G

ferritin heavy chain 1

multiple interactions
increases expression

HIPK2 protein promotes the reaction [Etoposide results in increased expression of FTH1 mRNA]

NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424

G

ferritin light chain 1

increases expression
multiple interactions

Etoposide results in increased expression of FTL mRNA; Etoposide results in increased expression of FTL protein
1-cyclopropyl-4-(4-((5-methyl-3-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)pyridin-2-yl)piperazine inhibits the reaction [Etoposide results in increased expression of FTL protein]; ARNT protein affects the reaction [Etoposide results in increased expression of FTL protein]; Etoposide promotes the reaction [HIF1A protein binds to FTL promoter]; FTL protein affects the reaction [Etoposide results in increased expression of ALDH1A1 protein]; FTL protein affects the reaction [Etoposide results in increased expression of KLF4 protein]; FTL protein affects the reaction [Etoposide results in increased expression of SOX2 protein]; HIF1A protein affects the reaction [Etoposide results in increased expression of FTL protein]

NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725
Ensembl chr10:95,936,387...95,939,725

G

fucosyltransferase 8

affects response to substance

FUT8 protein affects the susceptibility to Etoposide

NCBI chr 6:95,949,246...96,176,677
Ensembl chr 6:95,949,991...96,176,677

G

FYN proto-oncogene, Src family tyrosine kinase

affects response to substance
decreases expression

FYN protein affects the susceptibility to Etoposide
Etoposide results in decreased expression of FYN mRNA

PMID:16217747 PMID:25270620

NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911

G

frizzled class receptor 1

decreases expression

Etoposide results in decreased expression of FZD1 mRNA

NCBI chr 4:29,310,303...29,314,701
Ensembl chr 4:29,310,091...29,312,643
Ensembl chr 4:29,310,091...29,312,643

G

frizzled class receptor 5

decreases expression

Etoposide results in decreased expression of FZD5 mRNA

NCBI chr 9:66,113,096...66,120,276
Ensembl chr 9:66,113,112...66,121,457

G

growth arrest and DNA-damage-inducible, alpha

increases response to substance
multiple interactions
increases expression

GADD45A protein results in increased susceptibility to Etoposide
IKBKB protein inhibits the reaction [Etoposide results in increased expression of GADD45A protein]
Etoposide results in increased expression of GADD45A mRNA; Etoposide results in increased expression of GADD45A protein

PMID:19003803 PMID:21527772 PMID:29397400 PMID:30177839 PMID:31542801

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

glucosidase II alpha subunit

multiple interactions
decreases expression

[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of GANAB protein
Etoposide results in decreased expression of GANAB protein

NCBI chr 1:205,793,910...205,813,704
Ensembl chr 1:205,793,895...205,813,695

G

glyceraldehyde-3-phosphate dehydrogenase

increases expression

Etoposide results in increased expression of GAPDH protein

NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

[GCLC protein co-treated with GCLM protein] promotes the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; [GCLC protein co-treated with GCLM protein] results in decreased susceptibility to Etoposide

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

multiple interactions

[GCLC protein co-treated with GCLM protein] promotes the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; [GCLC protein co-treated with GCLM protein] results in decreased susceptibility to Etoposide

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

growth differentiation factor 15

multiple interactions
increases expression

Etoposide promotes the reaction [[TP53 protein binds to GDF15 promoter] which results in increased expression of GDF15 mRNA]
[Etoposide results in increased expression of TP53 protein] which results in increased expression of GDF15 protein; Etoposide results in increased expression of GDF15 mRNA; Etoposide results in increased expression of GDF15 protein

PMID:11895857 PMID:16120219 PMID:24211769 PMID:29397400

NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055

G

gap junction protein, alpha 1

multiple interactions
increases response to substance

GJA1 protein affects the reaction [Simvastatin results in increased susceptibility to Etoposide]; Tetradecanoylphorbol Acetate affects the reaction [GJA1 protein results in increased susceptibility to Etoposide]

NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582

G

gap junction protein, alpha 5

decreases expression

Etoposide results in decreased expression of GJA5 mRNA

NCBI chr 2:184,602,407...184,621,952
Ensembl chr 2:184,564,475...184,621,952

G

glutaminase 2

increases expression

Etoposide results in increased expression of GLS2 mRNA

PMID:21527772 PMID:29397400

NCBI chr 7:617,252...633,424
Ensembl chr 7:617,288...633,426

G

glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1

decreases expression

Etoposide results in decreased expression of GPIHBP1 mRNA

NCBI chr 7:107,285,584...107,288,702
Ensembl chr 7:107,285,654...107,288,702

G

glycoprotein m6b

affects response to substance

GPM6B protein affects the susceptibility to Etoposide

NCBI chr X:28,057,788...28,204,409
Ensembl chr X:28,059,450...28,204,211

G

glycoprotein nmb

increases expression

Etoposide results in increased expression of GPNMB mRNA

NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367

G

G protein-coupled receptor 37

affects response to substance

GPR37 protein affects the susceptibility to Etoposide

NCBI chr 4:54,138,860...54,160,927
Ensembl chr 4:54,138,870...54,161,001

G

G-protein signaling modulator 2

affects response to substance

GPSM2 protein affects the susceptibility to Etoposide

NCBI chr 2:196,327,149...196,375,322
Ensembl chr 2:196,327,149...196,375,154

G

glutathione peroxidase 1

increases expression

Etoposide results in increased expression of GPX1 mRNA

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutathione peroxidase 3

increases expression

Etoposide results in increased expression of GPX3 mRNA

NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035

G

glutamate ionotropic receptor AMPA type subunit 3

increases expression

Etoposide results in increased expression of GRIA3 mRNA

NCBI chr X:120,238,515...120,504,106
Ensembl chr X:120,238,534...120,504,096

G

GrpE-like 1, mitochondrial

decreases expression

Etoposide results in decreased expression of GRPEL1 mRNA

NCBI chr14:74,292,023...74,298,243
Ensembl chr14:74,292,023...74,298,200

G

glycogen synthase kinase 3 beta

multiple interactions
increases activity

BCL2 protein affects the reaction [[Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein]
[Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein; Etoposide results in increased activity of GSK3B protein

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

glutathione S-transferase mu 1

affects response to substance

GSTM1 gene polymorphism affects the susceptibility to Etoposide

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

glutathione S-transferase mu 4

affects response to substance

GSTM4 protein affects the susceptibility to Etoposide

NCBI chr 2:195,667,940...195,685,315
Ensembl chr 2:195,680,004...195,685,323

G

glutathione S-transferase pi 1

multiple interactions
decreases response to substance
affects response to substance

Curcumin inhibits the reaction [GSTP1 protein results in decreased susceptibility to Etoposide]; Ethacrynic Acid inhibits the reaction [GSTP1 protein results in decreased susceptibility to Etoposide]; GSTP1 protein promotes the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; Sulfinpyrazone inhibits the reaction [GSTP1 protein results in decreased susceptibility to Etoposide]; verlukast inhibits the reaction [GSTP1 protein results in decreased susceptibility to Etoposide]
GSTP1 gene polymorphism affects the susceptibility to Etoposide

PMID:10900222 PMID:12969965 PMID:15999103

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

glutathione S-transferase theta 2

affects response to substance

GSTT2 protein affects the susceptibility to Etoposide

NCBI chr20:12,819,617...12,823,288
Ensembl chr20:12,819,170...12,823,288

G

H2A.X variant histone

multiple interactions
increases expression
decreases response to substance
increases phosphorylation

Celecoxib inhibits the reaction [Etoposide results in increased phosphorylation of H2AX protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Etoposide results in increased phosphorylation of H2AX protein]; nimesulide inhibits the reaction [Etoposide results in increased phosphorylation of H2AX protein]; palbociclib inhibits the reaction [Etoposide results in increased expression of H2AX protein]; pifithrin promotes the reaction [Etoposide results in increased expression of H2AX protein]
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Etoposide results in increased expression of H2AX protein]; RAD54B protein affects the reaction [Etoposide results in increased expression of H2AX protein]; TOP2B protein affects the reaction [Etoposide results in increased expression of H2AX protein]
4,4'-(1,2-dimethyl-1,2-ethanediyl)bis-2,6-piperazinedione inhibits the reaction [Etoposide results in increased expression of H2AX protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Etoposide results in increased expression of H2AX protein]; Bortezomib inhibits the reaction [Etoposide results in increased expression of H2AX protein]; Razoxane inhibits the reaction [Etoposide results in increased expression of H2AX protein]
H2AX protein results in decreased susceptibility to Etoposide
Etoposide results in increased expression of H2AX protein; Etoposide results in increased expression of H2AX protein modified form

PMID:17875725 PMID:20643100 PMID:20978201 PMID:21555580 PMID:21745461 More...

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

histidine ammonia lyase

decreases expression

Etoposide results in decreased expression of HAL mRNA

NCBI chr 7:28,007,449...28,037,701
Ensembl chr 7:28,006,972...28,037,701

G

hepcidin antimicrobial peptide

decreases expression
multiple interactions

Etoposide results in decreased expression of HAMP mRNA
Etoposide inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]

PMID:25270620 PMID:25633564

NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891

G

heparin-binding EGF-like growth factor

increases expression

Etoposide results in increased expression of HBEGF mRNA

NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441

G

HMG-box transcription factor 1

decreases expression

Etoposide results in decreased expression of HBP1 mRNA

NCBI chr 6:48,529,633...48,555,775
Ensembl chr 6:48,529,372...48,555,787

G

histone deacetylase 4

affects response to substance

HDAC4 protein affects the susceptibility to Etoposide

NCBI chr 9:92,503,467...92,750,164
Ensembl chr 9:92,507,611...92,750,164

G

hephaestin

affects response to substance

HEPH protein affects the susceptibility to Etoposide

NCBI chr X:61,151,131...61,402,980
Ensembl chr X:61,296,345...61,402,980

G

HIC ZBTB transcriptional repressor 1

multiple interactions
increases expression

E2F1 protein affects the reaction [Etoposide results in increased expression of HIC1 mRNA]; Etoposide promotes the reaction [E2F1 protein binds to HIC1 promoter]

NCBI chr10:60,014,520...60,019,475
Ensembl chr10:60,011,528...60,019,475

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

Etoposide promotes the reaction [HIF1A protein binds to FTL promoter]; HIF1A mutant form inhibits the reaction [Oxygen deficiency results in decreased susceptibility to Etoposide]; HIF1A protein affects the reaction [Etoposide results in increased expression of FTL protein]

PMID:23144690 PMID:33969609

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

homeodomain interacting protein kinase 2

increases activity
multiple interactions
decreases response to substance

Etoposide results in increased activity of HIPK2 protein
HIPK2 gene mutant form inhibits the reaction [Etoposide results in increased expression of and results in increased phosphorylation of CREB1 protein]; HIPK2 gene mutant form promotes the reaction [Etoposide results in increased activity of CASP3 protein]; HIPK2 protein promotes the reaction [Etoposide results in increased expression of FTH1 mRNA]; HIPK2 protein promotes the reaction [Etoposide results in increased expression of NQO1 mRNA]
HIPK2 results in decreased susceptibility to Etoposide
HIPK2 mutant form inhibits the reaction [Etoposide results in increased expression of BDNF mRNA]

PMID:20573984 PMID:20980392

NCBI chr 4:67,439,327...67,619,223
Ensembl chr 4:67,440,501...67,619,223

G

5-hydroxymethylcytosine binding, ES cell specific

decreases expression

Etoposide results in decreased expression of HMCES mRNA

NCBI chr 4:120,392,812...120,415,616
Ensembl chr 4:120,366,542...120,415,616

G

high mobility group 20 B

affects response to substance

HMG20B protein affects the susceptibility to Etoposide

NCBI chr 7:8,368,934...8,373,650
Ensembl chr 7:8,368,990...8,373,640

G

high mobility group AT-hook 2

affects response to substance

HMGA2 protein affects the susceptibility to Etoposide

NCBI chr 7:55,877,145...55,998,813
Ensembl chr 7:55,880,112...55,994,784

G

high mobility group box 1

increases secretion
decreases response to substance

Etoposide results in increased secretion of HMGB1 protein
HMGB1 protein results in decreased susceptibility to Etoposide

NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

heterogeneous nuclear ribonucleoprotein H2

decreases expression

Etoposide results in decreased expression of HNRNPH2 protein

NCBI chr X:97,780,890...97,786,846
Ensembl chr X:97,780,785...97,787,041

G

homeo box A5

affects response to substance

HOXA5 protein affects the susceptibility to Etoposide

NCBI chr 4:81,302,341...81,306,234
Ensembl chr 4:81,302,353...81,306,234

G

heat shock protein 90 alpha family class A member 1

multiple interactions

[Bleomycin co-treated with Cisplatin co-treated with Etoposide] results in increased expression of HSP90AA1 protein

NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268

G

heat shock protein 90 beta family member 1

multiple interactions

[Bleomycin co-treated with Cisplatin co-treated with Etoposide] results in increased expression of HSP90B1 protein

NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788

G

heat shock protein family A (Hsp70) member 2

affects response to substance

HSPA2 protein affects the susceptibility to Etoposide

NCBI chr 6:95,128,504...95,131,281
Ensembl chr 6:95,128,350...95,131,287

G

heat shock protein family E (Hsp10) member 1

increases expression

Etoposide results in increased expression of HSPE1 protein

NCBI chr 9:56,589,912...56,593,000
Ensembl chr 9:56,589,789...56,593,089

G

HIV-1 Tat interactive protein 2

affects response to substance
increases response to substance
multiple interactions

HTATIP2 protein affects the susceptibility to Etoposide
HTATIP2 protein results in increased susceptibility to Etoposide
HTATIP2 protein promotes the reaction [Etoposide results in increased activity of CASP9 protein]; HTATIP2 protein promotes the reaction [Etoposide results in increased activity of PARP1 protein]

PMID:16217747 PMID:16799960

NCBI chr 1:99,473,411...99,488,632
Ensembl chr 1:99,469,245...99,488,629

G

5-hydroxytryptamine receptor 4

affects response to substance

HTR4 protein affects the susceptibility to Etoposide

NCBI chr18:55,765,981...55,949,921
Ensembl chr18:55,766,725...55,949,321

G

immediate early response 5

increases expression

Etoposide results in increased expression of IER5 mRNA

NCBI chr13:67,270,134...67,272,226
Ensembl chr13:67,270,135...67,272,227

G

interferon induced transmembrane protein 1

affects response to substance

IFITM1 protein affects the susceptibility to Etoposide

NCBI chr 1:196,067,163...196,069,169
Ensembl chr 1:196,067,963...196,069,169

G

immunoglobulin superfamily, DCC subclass, member 4

increases expression

Etoposide results in increased expression of IGDCC4 mRNA

NCBI chr 8:65,621,893...65,657,651
Ensembl chr 8:65,621,897...65,657,648

G

insulin-like growth factor 1 receptor

affects response to substance

IGF1R protein affects the susceptibility to Etoposide

NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777

G

insulin-like growth factor binding protein 7

affects response to substance

IGFBP7 protein affects the susceptibility to Etoposide

NCBI chr14:30,737,414...30,797,317
Ensembl chr14:30,737,164...30,797,314

G

immunoglobulin superfamily, member 11

decreases expression

Etoposide results in decreased expression of IGSF11 mRNA

NCBI chr11:61,733,139...61,884,059
Ensembl chr11:61,733,144...61,868,348

G

inhibitor of nuclear factor kappa B kinase subunit beta

affects response to substance
multiple interactions
decreases expression

IKBKB protein affects the susceptibility to Etoposide
DAPK1 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]; ETS1 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]; IKBKB protein inhibits the reaction [Etoposide results in increased expression of GADD45A protein]; IKBKB protein promotes the reaction [Etoposide results in increased expression of MDM2 protein modified form]; IKBKB protein promotes the reaction [Etoposide results in increased expression of MDM2 protein]; TP53 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]

PMID:20159942 PMID:30177839

NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250

G

interleukin 1 beta

increases expression

Etoposide results in increased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 4

decreases response to substance
multiple interactions

IL4 protein results in decreased susceptibility to Etoposide
[IL4 protein co-treated with VCAM1 protein] inhibits the reaction [Etoposide results in decreased folding of BAX protein]; [VCAM1 protein co-treated with IL4 protein] inhibits the reaction [Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]]; [VCAM1 protein co-treated with IL4 protein] results in decreased susceptibility to Etoposide

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 6

multiple interactions
increases expression
increases secretion

(4-(5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl)pyridin-2-yl)-(1-phenylethyl)amine inhibits the reaction [Etoposide results in increased expression of IL6 mRNA]; (4-(5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl)pyridin-2-yl)-(1-phenylethyl)amine inhibits the reaction [Etoposide results in increased secretion of IL6 protein]
Etoposide results in increased expression of IL6 mRNA; Etoposide results in increased expression of IL6 protein

PMID:15135310 PMID:17003255 PMID:18523641

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

inka box actin regulator 2

increases expression

Etoposide results in increased expression of INKA2 mRNA

NCBI chr 2:193,185,275...193,200,643
Ensembl chr 2:193,185,275...193,200,642

G

insulin induced gene 1

affects response to substance

INSIG1 protein affects the susceptibility to Etoposide

NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952

G

integrator complex subunit 15

decreases expression

Etoposide results in decreased expression of INTS15 mRNA

NCBI chr12:11,245,045...11,260,170
Ensembl chr12:11,245,842...11,260,166

G

iron responsive element binding protein 2

multiple interactions
decreases expression

1-cyclopropyl-4-(4-((5-methyl-3-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)pyridin-2-yl)piperazine inhibits the reaction [Etoposide results in decreased expression of IREB2 protein]
Etoposide results in decreased expression of IREB2 mRNA; Etoposide results in decreased expression of IREB2 protein

NCBI chr 8:55,228,080...55,311,613
Ensembl chr 8:55,228,085...55,311,611

G

insulin receptor substrate 2

affects response to substance

IRS2 protein affects the susceptibility to Etoposide

NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482

G

iroquois homeobox 4

decreases expression

Etoposide results in decreased expression of IRX4 mRNA

NCBI chr 1:30,030,561...30,039,549
Ensembl chr 1:30,030,561...30,039,549

G

ISG15 ubiquitin-like modifier

increases expression

Etoposide results in increased expression of ISG15 mRNA

NCBI chr 5:166,784,148...166,785,435
Ensembl chr 5:166,784,148...166,785,435

G

interferon stimulated exonuclease gene 20

affects response to substance

ISG20 protein affects the susceptibility to Etoposide

NCBI chr 1:132,829,303...132,837,027
Ensembl chr 1:132,815,123...132,837,027

G

interferon stimulated exonuclease gene 20-like 2

decreases expression

Etoposide results in decreased expression of ISG20L2 mRNA

NCBI chr 2:173,396,780...173,407,102
Ensembl chr 2:173,396,780...173,406,614

G

integrin subunit alpha 2b

increases expression

Etoposide results in increased expression of ITGA2B mRNA

NCBI chr10:87,408,532...87,426,055
Ensembl chr10:87,408,536...87,426,168

G

integrin subunit beta 3

increases response to substance

ITGB3 protein results in increased susceptibility to Etoposide

NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679

G

inositol 1,4,5-trisphosphate receptor, type 1

affects response to substance

ITPR1 protein affects the susceptibility to Etoposide

NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[Etoposide co-treated with Cyclic AMP] results in increased expression of JUN mRNA

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

potassium voltage-gated channel subfamily A regulatory beta subunit 2

affects response to substance

KCNAB2 protein affects the susceptibility to Etoposide

NCBI chr 5:162,899,511...162,988,057
Ensembl chr 5:162,901,896...162,988,243

G

potassium voltage-gated channel subfamily E regulatory subunit 3

decreases expression

Etoposide results in decreased expression of KCNE3 mRNA

NCBI chr 1:154,523,903...154,530,865
Ensembl chr 1:154,523,830...154,532,020

G

potassium calcium-activated channel subfamily N member 2

decreases expression

Etoposide results in decreased expression of KCNN2 mRNA

NCBI chr18:37,817,966...38,258,347
Ensembl chr18:37,817,957...38,258,347

G

Kelch-like ECH-associated protein 1

decreases response to substance
multiple interactions
increases response to substance

KEAP1 protein results in decreased susceptibility to Etoposide
KEAP1 protein affects the reaction [Etoposide results in increased expression of CDKN1A protein]
KEAP1 mRNA results in increased susceptibility to Etoposide

PMID:22684020 PMID:26708503 PMID:27982581

NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862

G

kinesin family member 1A

increases expression

Etoposide results in increased expression of KIF1A mRNA

NCBI chr 9:93,563,033...93,647,412
Ensembl chr 9:93,563,045...93,647,480

G

kinesin family member 20A

decreases expression

Etoposide results in decreased expression of KIF20A mRNA

NCBI chr18:26,230,294...26,238,780
Ensembl chr18:26,230,230...26,238,780

G

kinesin family member 23

decreases expression

Etoposide results in decreased expression of KIF23 mRNA

NCBI chr 8:62,397,908...62,425,162
Ensembl chr 8:62,397,948...62,425,072

G

KIT proto-oncogene receptor tyrosine kinase

multiple interactions
increases expression

[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in increased expression of KIT protein
Etoposide results in increased expression of KIT protein

NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652

G

KLF transcription factor 4

increases expression
multiple interactions

Etoposide results in increased expression of KLF4 mRNA; Etoposide results in increased expression of KLF4 protein
FTL protein affects the reaction [Etoposide results in increased expression of KLF4 protein]

NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602

G

KLF transcription factor 5

increases expression

Etoposide results in increased expression of KLF5 mRNA

NCBI chr15:76,060,320...76,079,445
Ensembl chr15:76,064,258...76,079,445

G

KLF transcription factor 6

decreases expression

Etoposide results in decreased expression of KLF6 mRNA

NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570

G

kelch-like family member 26

increases expression

Etoposide results in increased expression of KLHL26 mRNA

NCBI chr16:18,952,123...18,977,328
Ensembl chr16:18,952,234...18,977,328

G

kallikrein 1-related peptidase C10

multiple interactions

Etoposide inhibits the reaction [Dihydrotestosterone results in increased expression of KLK3 mRNA]

NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052

G

lysine methyltransferase 2A

increases response to substance
increases mutagenesis
increases cleavage

KMT2A gene mutant form results in increased susceptibility to Etoposide
Etoposide results in increased mutagenesis of KMT2A gene
Etoposide results in increased cleavage of KMT2A gene

PMID:14712291 PMID:24086652 PMID:28624474

NCBI chr 8:45,116,763...45,193,320
Ensembl chr 8:45,118,814...45,193,181

G

keratin 19

increases expression

Etoposide results in increased expression of KRT19 mRNA

NCBI chr10:85,075,835...85,080,552
Ensembl chr10:85,066,802...85,171,799

G

keratin 80

increases expression

Etoposide results in increased expression of KRT80 mRNA

NCBI chr 7:132,463,216...132,485,134
Ensembl chr 7:132,463,218...132,485,508

G

kynureninase

affects response to substance

KYNU protein affects the susceptibility to Etoposide

NCBI chr 3:27,778,646...27,929,470
Ensembl chr 3:27,778,772...27,929,488

G

LanC like glutathione S-transferase 1

affects response to substance

LANCL1 protein affects the susceptibility to Etoposide

NCBI chr 9:68,515,052...68,548,646
Ensembl chr 9:68,518,574...68,548,628

G

leucine aminopeptidase 3

decreases expression

Etoposide results in decreased expression of LAP3 mRNA

NCBI chr14:65,608,375...65,627,359
Ensembl chr14:65,608,376...65,627,359

G

lipocalin 2

increases response to substance

LCN2 protein results in increased susceptibility to Etoposide

NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095

G

LIM domain binding 3

decreases expression

Etoposide results in decreased expression of LDB3 mRNA

NCBI chr16:9,855,768...9,920,108
Ensembl chr16:9,855,927...9,918,532

G

galectin 3

affects response to substance

LGALS3 protein affects the susceptibility to Etoposide

NCBI chr15:20,620,083...20,632,019
Ensembl chr15:20,607,692...20,632,025

G

galectin 7

increases expression

Etoposide results in increased expression of LGALS7 mRNA

NCBI chr 1:84,148,612...84,152,016
Ensembl chr 1:84,150,252...84,152,015

G

LIM homeobox 1

multiple interactions
decreases expression

[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of LHX1 mRNA
Etoposide results in decreased expression of LHX1 mRNA

NCBI chr10:69,396,829...69,403,617
Ensembl chr10:69,396,829...69,403,617

G

LIM homeobox 2

decreases expression

Etoposide results in decreased expression of LHX2 mRNA

NCBI chr 3:22,113,619...22,143,909
Ensembl chr 3:22,126,007...22,143,908

G

LIF, interleukin 6 family cytokine

increases expression

Etoposide results in increased expression of LIF mRNA

NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482

G

LIM and calponin homology domains 1

affects response to substance

LIMCH1 protein affects the susceptibility to Etoposide

NCBI chr14:41,112,579...41,425,001
Ensembl chr14:41,114,803...41,425,191

G

lipase A, lysosomal acid type

affects response to substance

LIPA protein affects the susceptibility to Etoposide

NCBI chr 1:232,024,351...232,057,735
Ensembl chr 1:232,024,356...232,057,633

G

leucine rich repeat containing 47

decreases expression

Etoposide results in decreased expression of LRRC47 mRNA

NCBI chr 5:164,570,539...164,580,174
Ensembl chr 5:164,570,435...164,580,174

G

lymphotoxin beta receptor

multiple interactions
increases expression

Estradiol inhibits the reaction [Etoposide results in increased expression of LTBR mRNA]

NCBI chr 4:158,108,884...158,115,339
Ensembl chr 4:158,108,886...158,121,539

G

latexin

increases response to substance

LXN protein results in increased susceptibility to Etoposide

NCBI chr 2:151,727,556...151,733,426
Ensembl chr 2:151,727,102...151,733,460

G

lymphocyte antigen 6 family member E

affects response to substance

LY6E protein affects the susceptibility to Etoposide

NCBI chr 7:106,935,530...106,939,689
Ensembl chr 7:106,935,761...106,939,689

G

microtubule-actin crosslinking factor 1

affects response to substance

MACF1 protein affects the susceptibility to Etoposide

NCBI chr 5:135,623,734...135,949,097
Ensembl chr 5:135,623,742...135,945,905

G

mannosidase, alpha, class 2B, member 1

increases expression

Etoposide results in increased expression of MAN2B1 mRNA

NCBI chr19:23,055,092...23,074,398
Ensembl chr19:23,055,097...23,074,389

G

mitogen activated protein kinase kinase 3

increases expression

Etoposide results in increased expression of MAP2K3 mRNA

NCBI chr10:45,608,145...45,629,492
Ensembl chr10:45,607,163...45,629,492

G

mitogen-activated protein kinase kinase kinase 5

decreases expression

Etoposide results in decreased expression of MAP3K5 mRNA

NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800

G

microtubule-associated protein 7

affects response to substance

MAP7 protein affects the susceptibility to Etoposide

NCBI chr 1:14,910,433...15,037,574
Ensembl chr 1:14,910,551...15,037,574

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

3',4'-dihydroxyflavone analog inhibits the reaction [Etoposide results in increased phosphorylation of MAPK1 protein]; Acetylcysteine inhibits the reaction [Etoposide results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Etoposide results in increased phosphorylation of MAPK1 protein]

PMID:16014620 PMID:19720055 PMID:26046675

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen-activated protein kinase 12

increases activity
affects response to substance
multiple interactions

Etoposide results in increased activity of MAPK12 protein
MAPK12 protein affects the susceptibility to Etoposide
[MAPK12 protein results in increased phosphorylation of TOP2A protein] which results in increased susceptibility to Etoposide; [MAPK12 protein results in increased stability of TOP2A protein] which results in increased susceptibility to Etoposide

NCBI chr 7:120,206,005...120,216,711
Ensembl chr 7:120,206,271...120,216,664

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

3',4'-dihydroxyflavone analog inhibits the reaction [Etoposide results in increased phosphorylation of MAPK3 protein]; Acetylcysteine inhibits the reaction [Etoposide results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Etoposide results in increased phosphorylation of MAPK3 protein]

PMID:16014620 PMID:19720055 PMID:26046675

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

MAPK activated protein kinase 2

multiple interactions
increases phosphorylation

(4-(5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl)pyridin-2-yl)-(1-phenylethyl)amine inhibits the reaction [Etoposide results in increased phosphorylation of MAPKAPK2 protein]

NCBI chr13:42,513,762...42,560,061
Ensembl chr13:42,513,762...42,560,457

G

matrilin 2

affects response to substance

MATN2 protein affects the susceptibility to Etoposide

NCBI chr 7:65,494,996...65,644,613
Ensembl chr 7:65,494,834...65,645,113

G

myelin basic protein

affects response to substance

MBP protein affects the susceptibility to Etoposide

NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404

G

melanoma cell adhesion molecule

increases expression

Etoposide results in increased expression of MCAM mRNA

NCBI chr 8:44,479,391...44,487,575
Ensembl chr 8:44,479,376...44,487,571

G

MCL1 apoptosis regulator, BCL2 family member

multiple interactions
decreases expression

wortmannin promotes the reaction [Etoposide results in decreased expression of MCL1 protein]

NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303

G

minichromosome maintenance 10 replication initiation factor

decreases expression

Etoposide results in decreased expression of MCM10 mRNA

NCBI chr17:73,263,788...73,288,346
Ensembl chr17:73,266,095...73,287,364

G

minichromosome maintenance complex component 2

decreases expression

Etoposide results in decreased expression of MCM2 mRNA

NCBI chr 4:121,346,434...121,360,962
Ensembl chr 4:121,346,434...121,360,847

G

minichromosome maintenance complex component 6

decreases expression

Etoposide results in decreased expression of MCM6 mRNA

NCBI chr13:39,826,745...39,851,937
Ensembl chr13:39,826,763...39,851,960

G

minichromosome maintenance complex component 7

decreases expression

Etoposide results in decreased expression of MCM7 mRNA

NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063

G

minichromosome maintenance 8 homologous recombination repair factor

decreases expression

Etoposide results in decreased expression of MCM8 mRNA

NCBI chr 3:120,086,741...120,117,008
Ensembl chr 3:120,086,763...120,117,008

G

MyoD family inhibitor domain containing

affects response to substance

MDFIC protein affects the susceptibility to Etoposide

NCBI chr 4:43,972,310...44,052,162
Ensembl chr 4:43,972,507...44,052,161

G

malate dehydrogenase 2

multiple interactions

[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of MDH2 protein

NCBI chr12:20,894,269...20,907,225
Ensembl chr12:20,894,262...20,907,271

G

MDM2 proto-oncogene

multiple interactions
decreases expression
increases phosphorylation
increases expression
decreases response to substance

benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Etoposide promotes the reaction [MDM2 protein binds to TOP2A protein]]; Cadmium Chloride affects the reaction [Etoposide results in increased phosphorylation of MDM2 protein]; Etoposide promotes the reaction [MDM2 protein binds to TOP2A protein]; IKBKB protein promotes the reaction [Etoposide results in increased expression of MDM2 protein modified form]; IKBKB protein promotes the reaction [Etoposide results in increased expression of MDM2 protein]; Wortmannin promotes the reaction [Etoposide results in increased phosphorylation of MDM2 protein]
Etoposide results in decreased expression of MDM2 protein
Etoposide results in increased expression of MDM2 mRNA; Etoposide results in increased expression of MDM2 protein; Etoposide results in increased expression of MDM2 protein modified form
Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased expression of MDM2 protein]
MDM2 promoter SNP results in decreased susceptibility to Etoposide

PMID:15459018 PMID:16120219 PMID:17575151 PMID:17935137 PMID:18096571 More...

NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915

G

malic enzyme 2

decreases expression

Etoposide results in decreased expression of ME2 protein

NCBI chr18:67,350,833...67,400,987
Ensembl chr18:67,355,795...67,400,987

G

microRNA 135b

increases expression

Etoposide results in increased expression of MIR135B mRNA

NCBI chr13:43,638,857...43,638,953
Ensembl chr13:43,638,857...43,638,953

G

microRNA 139

increases expression

Etoposide results in increased expression of MIR139 mRNA

NCBI chr 1:155,878,828...155,878,895
Ensembl chr 1:155,878,825...155,878,902

G

microRNA 196b

increases expression

Etoposide results in increased expression of MIR196B mRNA

NCBI chr 4:81,330,487...81,330,571
Ensembl chr 4:81,330,487...81,330,571

G

microRNA 34c

increases expression

Etoposide results in increased expression of MIR34C mRNA

NCBI chr 8:51,409,726...51,409,802
Ensembl chr 8:51,409,726...51,409,802

G

melan-A

affects response to substance

MLANA protein affects the susceptibility to Etoposide

NCBI chr 1:227,469,537...227,483,343
Ensembl chr 1:227,469,537...227,483,343

G

MLLT11, transcription factor 7 cofactor

affects response to substance

MLLT11 protein affects the susceptibility to Etoposide

NCBI chr 2:182,795,790...182,804,960
Ensembl chr 2:182,795,790...182,797,199

G

matrix metallopeptidase 1

decreases expression
multiple interactions

Etoposide results in decreased expression of MMP1 protein
pifithrin inhibits the reaction [Etoposide results in decreased expression of MMP1 protein]

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

G

molybdenum cofactor sulfurase

affects response to substance

MOCOS protein affects the susceptibility to Etoposide

NCBI chr18:15,931,659...15,977,415
Ensembl chr18:15,931,654...15,977,187

G

myeloperoxidase

increases metabolic processing

MPO protein results in increased metabolism of Etoposide

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

myelin protein zero-like 1

decreases expression

Etoposide results in decreased expression of MPZL1 mRNA

NCBI chr13:77,852,467...77,889,305
Ensembl chr13:77,852,467...77,896,616

G

major histocompatibility complex, class I-related

increases expression
affects expression

Etoposide results in increased expression of MR1 mRNA
Etoposide affects the expression of MR1 mRNA

PMID:21527772 PMID:25811541

NCBI chr13:67,298,362...67,317,985
Ensembl chr13:67,299,585...67,317,970

G

muscle RAS oncogene homolog

decreases expression

Etoposide results in decreased expression of MRAS mRNA

NCBI chr 8:99,944,036...100,006,771
Ensembl chr 8:99,944,036...99,996,408

G

mannose receptor, C type 1

decreases expression

Etoposide results in decreased expression of MRC1 mRNA

NCBI chr17:77,249,187...77,330,857
Ensembl chr17:77,249,187...77,330,857

G

mitochondrial rRNA methyltransferase 2

decreases expression

Etoposide results in decreased expression of MRM2 mRNA

NCBI chr12:14,309,556...14,314,759
Ensembl chr12:14,251,941...14,314,118

G

musculin

decreases expression

Etoposide results in decreased expression of MSC mRNA

NCBI chr 5:4,547,335...4,553,206
Ensembl chr 5:4,547,405...4,553,203

G

mutS homolog 6

decreases expression

Etoposide results in decreased expression of MSH6 mRNA

NCBI chr 6:6,562,631...6,579,995
Ensembl chr 6:6,562,632...6,579,956

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4

increases expression

Etoposide results in increased expression of ND4 mRNA

NCBI chr MT:10,160...11,537
NCBI chr MT:10,160...11,537
NCBI chr MT:10,160...11,537
NCBI chr MT:10,160...11,537
NCBI chr MT:10,160...11,537
NCBI chr MT:10,160...11,537
NCBI chr MT:10,160...11,537
NCBI chr MT:10,160...11,537
Ensembl chr MT:10,160...11,537

G

metallothionein 2A

decreases expression
multiple interactions

Etoposide results in decreased expression of MT2A protein
XAF1 protein affects the reaction [Etoposide results in decreased expression of MT2A protein]

NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase

decreases expression

Etoposide results in decreased expression of MTHFD2 mRNA

NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608

G

mechanistic target of rapamycin kinase

increases phosphorylation

Etoposide results in increased phosphorylation of MTOR protein

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

microtubule associated scaffold protein 1

affects response to substance

MTUS1 protein affects the susceptibility to Etoposide

NCBI chr16:51,202,497...51,347,794
Ensembl chr16:51,253,562...51,347,793

G

MAX interactor 1, dimerization protein

affects response to substance

MXI1 protein affects the susceptibility to Etoposide

NCBI chr 1:252,323,915...252,383,682
Ensembl chr 1:252,323,303...252,383,681

G

MYC proto-oncogene, bHLH transcription factor

decreases expression
increases response to substance
multiple interactions

Etoposide results in decreased expression of MYC; Etoposide results in decreased expression of MYC mRNA
MYC protein results in increased susceptibility to Etoposide
MYC protein promotes the reaction [Etoposide results in increased cleavage of CASP9 protein]

PMID:9454737 PMID:21324178 PMID:21527772

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

MYCN proto-oncogene, bHLH transcription factor

multiple interactions
decreases response to substance

[MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to Etoposide
MYCN protein results in decreased susceptibility to Etoposide

NCBI chr 6:35,717,764...35,723,590
Ensembl chr 6:35,717,764...35,723,590

G

myosin heavy chain 7

decreases expression

Etoposide results in decreased expression of MYH7 mRNA

NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217

G

myosin light chain 2

decreases expression

Etoposide results in decreased expression of MYL2 mRNA

NCBI chr12:34,454,223...34,468,554
Ensembl chr12:34,454,218...34,468,983

G

myosin light chain 3

decreases expression

Etoposide results in decreased expression of MYL3 mRNA

NCBI chr 8:110,738,669...110,744,814
Ensembl chr 8:110,738,661...110,744,816

G

myomesin 2

decreases expression

Etoposide results in decreased expression of MYOM2 mRNA

NCBI chr16:74,520,148...74,592,658
Ensembl chr16:74,520,157...74,592,772

G

myotilin

increases expression

Etoposide results in increased expression of MYOT mRNA

NCBI chr18:36,705,244...36,724,849
Ensembl chr18:36,705,314...36,724,841

G

myelin transcription factor 1

decreases expression

Etoposide results in decreased expression of MYT1 mRNA

NCBI chr 3:168,890,466...168,950,341
Ensembl chr 3:168,886,089...168,950,341

G

nucleic acid binding protein 2

multiple interactions
increases acetylation

4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid inhibits the reaction [Etoposide results in increased acetylation of NABP2 protein]

NCBI chr 7:830,949...836,551
Ensembl chr 7:830,949...838,027

G

nucleosome assembly protein 1-like 1

affects response to substance

NAP1L1 protein affects the susceptibility to Etoposide

NCBI chr 7:46,933,278...46,957,853
Ensembl chr 7:46,933,356...46,956,593

G

NCK adaptor protein 2

decreases expression

Etoposide results in decreased expression of NCK2 mRNA

NCBI chr 9:45,713,979...45,840,330
Ensembl chr 9:45,714,883...45,840,307

G

nectin cell adhesion molecule 2

decreases expression

Etoposide results in decreased expression of NECTIN2 mRNA

NCBI chr 1:79,372,123...79,407,379
Ensembl chr 1:79,372,119...79,407,360

G

neural precursor cell expressed, developmentally down-regulated 9

affects response to substance

NEDD9 protein affects the susceptibility to Etoposide

NCBI chr17:23,289,793...23,468,026
Ensembl chr17:23,282,326...23,468,019

G

NIMA-related kinase 2

decreases expression

Etoposide results in decreased expression of NEK2 mRNA

NCBI chr13:103,405,818...103,419,063
Ensembl chr13:103,405,819...103,419,051

G

NFE2 like bZIP transcription factor 2

decreases response to substance
multiple interactions

NFE2L2 mRNA results in decreased susceptibility to Etoposide; NFE2L2 protein results in decreased susceptibility to Etoposide
NFE2L2 protein affects the reaction [Etoposide results in increased expression of SRXN1 protein]; NFE2L2 protein affects the reaction [Etoposide results in increased expression of TP53 protein]; trigonelline inhibits the reaction [NFE2L2 protein results in decreased susceptibility to Etoposide]

PMID:26708503 PMID:27982581 PMID:33148531

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor kappa B subunit 1

multiple interactions

NFKB1 protein affects the reaction [Etoposide results in increased expression of TP53 protein]; NFKB1 protein affects the reaction [Etoposide results in increased phosphorylation of AKT1 protein]

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

NFKB inhibitor alpha

multiple interactions
increases degradation

wortmannin inhibits the reaction [Etoposide results in increased degradation of NFKBIA protein]

PMID:12637521 PMID:17935137

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

NHERF family PDZ scaffold protein 1

increases expression

Etoposide results in increased expression of NHERF1 mRNA

NCBI chr10:100,403,189...100,420,290
Ensembl chr10:100,403,069...100,420,598

G

niban apoptosis regulator 1

affects response to substance

NIBAN1 protein affects the susceptibility to Etoposide

NCBI chr13:63,674,240...63,827,748
Ensembl chr13:63,674,171...63,827,729

G

nitrilase family, member 2

multiple interactions

[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of NIT2 protein

NCBI chr11:43,363,839...43,378,713
Ensembl chr11:43,363,985...43,375,024

G

N-myristoyltransferase 2

affects response to substance

NMT2 protein affects the susceptibility to Etoposide

NCBI chr17:74,917,833...74,964,788
Ensembl chr17:74,917,833...74,961,080

G

nitric oxide synthase 2

increases expression

Etoposide results in increased expression of NOS2 mRNA
Etoposide results in increased expression of NOS2 protein

PMID:15135310 PMID:26259609

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

neuronal PAS domain protein 1

increases expression

Etoposide results in increased expression of NPAS1 mRNA

NCBI chr 1:77,167,375...77,187,887
Ensembl chr 1:77,167,381...77,186,762

G

nephronectin

increases expression

Etoposide results in increased expression of NPNT mRNA

NCBI chr 2:221,391,151...221,459,527
Ensembl chr 2:221,391,153...221,459,401

G

NAD(P)H quinone dehydrogenase 1

affects response to substance
increases expression
multiple interactions

NQO1 protein affects the susceptibility to Etoposide
Etoposide results in increased expression of NQO1 mRNA
HIPK2 protein promotes the reaction [Etoposide results in increased expression of NQO1 mRNA]

PMID:16217747 PMID:20980392 PMID:29397400

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 0, group B, member 1

decreases expression

Etoposide results in decreased expression of NR0B1 mRNA

NCBI chr X:50,756,886...50,761,014
Ensembl chr X:50,756,886...50,761,011

G

nuclear receptor subfamily 1, group H, member 2

affects localization
affects response to substance
multiple interactions

Etoposide affects the localization of NR1H2 protein
NR1H2 protein affects the susceptibility to Etoposide
Etoposide promotes the reaction [NR1H2 protein results in increased expression of CETP mRNA]; NR1H2 mutant form inhibits the reaction [Etoposide results in increased expression of CETP mRNA]

NCBI chr 1:95,041,967...95,047,358
Ensembl chr 1:95,041,967...95,047,377

G

nuclear receptor subfamily 1, group H, member 3

multiple interactions
affects response to substance
increases expression

Etoposide promotes the reaction [NR1H3 protein results in increased expression of CETP mRNA]; Etoposide results in increased expression of and affects the localization of NR1H3 protein; NR1H3 mutant form inhibits the reaction [Etoposide results in increased expression of CETP mRNA]
NR1H3 protein affects the susceptibility to Etoposide
Etoposide results in increased expression of NR1H3 mRNA

NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722

G

nuclear receptor subfamily 1, group I, member 2

affects response to substance
multiple interactions
increases activity

NR1I2 protein affects the susceptibility to Etoposide
[Etoposide results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA

PMID:17279585 PMID:25455453

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 1, group I, member 3

multiple interactions

Etoposide inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein]

NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906

G

nebulin-related anchoring protein

decreases expression

Etoposide results in decreased expression of NRAP mRNA

NCBI chr 1:255,350,113...255,427,704
Ensembl chr 1:255,350,113...255,427,693

G

neuregulin 1

increases expression

Etoposide results in increased expression of NRG1 mRNA

NCBI chr16:59,250,658...60,304,519
Ensembl chr16:59,250,854...60,296,884

G

nuclear receptor interacting protein 1

affects response to substance
decreases expression

NRIP1 protein affects the susceptibility to Etoposide
Etoposide results in decreased expression of NRIP1 mRNA; Etoposide results in decreased expression of NRIP1 protein

PMID:16217747 PMID:25914138

NCBI chr11:14,895,843...14,979,490
Ensembl chr11:14,895,553...14,981,761

G

nuclear protein 1, transcriptional regulator

affects response to substance
decreases expression

NUPR1 protein affects the susceptibility to Etoposide
Etoposide results in decreased expression of NUPR1 mRNA

PMID:16217747 PMID:25270620

NCBI chr 1:181,213,292...181,215,327
Ensembl chr 1:181,213,368...181,215,281

G

ornithine aminotransferase

multiple interactions

[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of OAT protein

NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682

G

OCA2 melanosomal transmembrane protein

affects response to substance

OCA2 protein affects the susceptibility to Etoposide

NCBI chr 1:107,116,278...107,446,093
Ensembl chr 1:107,116,278...107,446,074

G

8-oxoguanine DNA glycosylase

decreases expression
multiple interactions

Etoposide results in decreased expression of OGG1 mRNA
wogonin inhibits the reaction [Etoposide results in decreased expression of OGG1 mRNA]

NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766

G

purinergic receptor P2X 7

increases expression

Etoposide results in increased expression of P2RX7 mRNA

NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619

G

poly(A) binding protein, cytoplasmic 1

decreases expression

Etoposide results in decreased expression of PABPC1 protein

NCBI chr 7:67,777,438...67,789,731
Ensembl chr 7:67,777,381...67,789,744

G

partner and localizer of BRCA2

decreases expression

Etoposide results in decreased expression of PALB2 mRNA

NCBI chr 1:176,665,076...176,689,053
Ensembl chr 1:176,665,076...176,688,990

G

3'-phosphoadenosine 5'-phosphosulfate synthase 2

increases expression

Etoposide results in increased expression of PAPSS2 mRNA

NCBI chr 1:230,454,314...230,539,332
Ensembl chr 1:230,454,426...230,539,331

G

poly (ADP-ribose) polymerase 1

increases cleavage
multiple interactions
increases degradation

Etoposide results in increased cleavage of PARP1 protein
3',4'-dihydroxyflavone analog inhibits the reaction [Etoposide results in increased cleavage of PARP1 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of PARP1 protein]; [Colforsin co-treated with Theophylline] inhibits the reaction [Etoposide results in increased cleavage of PARP1 protein]; [trigonelline co-treated with Etoposide] results in increased cleavage of PARP1 protein; BCL2 protein inhibits the reaction [Etoposide results in increased degradation of PARP1 protein]; BCL2L1 protein inhibits the reaction [Etoposide results in increased degradation of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane inhibits the reaction [Etoposide results in increased cleavage of PARP1 protein]; CD40LG protein inhibits the reaction [Etoposide promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]]; Etoposide promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]; HTATIP2 protein promotes the reaction [Etoposide results in increased activity of PARP1 protein]; Nicotine inhibits the reaction [Etoposide results in increased cleavage of PARP1 protein]; PTEN protein modified form promotes the reaction [Etoposide results in increased cleavage of PARP1 protein]; PTEN protein promotes the reaction [Etoposide results in increased cleavage of PARP1 protein]; Wortmannin promotes the reaction [Etoposide results in increased cleavage of PARP1 protein]; XAF1 protein affects the reaction [Etoposide results in increased cleavage of PARP1 protein]
Niacin deficiency affects the reaction [Etoposide results in increased cleavage of PARP1 protein]

PMID:8840993 PMID:9454737 PMID:12690110 PMID:16014620 PMID:16545138 More...

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

PDZ binding kinase

affects response to substance

PBK protein affects the susceptibility to Etoposide

NCBI chr15:40,022,873...40,034,014
Ensembl chr15:40,023,002...40,034,014

G

poly(rC) binding protein 2

multiple interactions

[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of PCBP2 protein

NCBI chr 7:133,605,375...133,631,312
Ensembl chr 7:133,605,573...133,629,863

G

poly(rC) binding protein 4

decreases expression

Etoposide results in decreased expression of PCBP4 mRNA

NCBI chr 8:107,092,688...107,103,276
Ensembl chr 8:107,093,013...107,103,276

G

phosphoenolpyruvate carboxykinase 2 (mitochondrial)

decreases expression

Etoposide results in decreased expression of PCK2 mRNA

NCBI chr15:29,027,891...29,036,729
Ensembl chr15:29,027,894...29,037,283

G

phosphodiesterase 2A

decreases expression

Etoposide results in decreased expression of PDE2A mRNA

NCBI chr 1:155,823,590...155,915,434
Ensembl chr 1:155,813,180...155,915,434

G

phosphodiesterase 4B

affects response to substance

PDE4B protein affects the susceptibility to Etoposide

NCBI chr 5:116,799,819...117,369,155
Ensembl chr 5:116,799,971...117,367,696

G

platelet derived growth factor C

affects response to substance

PDGFC protein affects the susceptibility to Etoposide

NCBI chr 2:166,316,870...166,493,449
Ensembl chr 2:166,316,803...166,493,433

G

protein disulfide isomerase family A, member 3

multiple interactions

[Bleomycin co-treated with Cisplatin co-treated with Etoposide] results in increased expression of PDIA3 protein

NCBI chr 3:108,388,189...108,412,013
Ensembl chr 3:108,388,245...108,413,236

G

pyruvate dehydrogenase kinase 1

decreases expression

Etoposide results in decreased expression of PDK1 mRNA

NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038

G

pyruvate dehydrogenase kinase 4

increases expression

Etoposide results in increased expression of PDK4 mRNA

NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850

G

PDZ and LIM domain 3

increases expression

Etoposide results in increased expression of PDLIM3 mRNA

NCBI chr16:46,352,460...46,383,680
Ensembl chr16:46,352,467...46,383,657

G

pelota mRNA surveillance and ribosome rescue factor

decreases expression

Etoposide results in decreased expression of PELO mRNA

NCBI chr 2:46,797,853...46,799,621
Ensembl chr 2:46,797,853...46,799,746

G

p53 apoptosis effector related to PMP22

increases expression

Etoposide results in increased expression of PERP mRNA

PMID:21382384 PMID:25270620

NCBI chr 1:13,542,067...13,554,514
Ensembl chr 1:13,542,067...13,554,511

G

phosphoglycerate dehydrogenase

affects response to substance

PHGDH protein affects the susceptibility to Etoposide

NCBI chr 2:185,906,962...185,936,054
Ensembl chr 2:185,906,966...185,935,944

G

pleckstrin homology-like domain, family A, member 3

increases expression

Etoposide results in increased expression of PHLDA3 mRNA

NCBI chr13:47,193,250...47,196,335
Ensembl chr13:47,193,086...47,196,335

G

phosphatidylinositol glycan anchor biosynthesis, class A

multiple interactions

[Cisplatin co-treated with Etoposide] results in increased mutagenesis of PIGA

NCBI chr X:30,043,033...30,055,861
Ensembl chr X:30,042,343...30,055,804

G

phosphatidylinositol-4-phosphate 5-kinase type 1 beta

affects response to substance

PIP5K1B protein affects the susceptibility to Etoposide

NCBI chr 1:221,907,220...222,183,672
Ensembl chr 1:221,914,159...222,183,672

G

plasminogen activator, urokinase

increases expression

Etoposide results in increased expression of PLAU mRNA

NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775

G

polo-like kinase 1

decreases expression

Etoposide results in decreased expression of PLK1 mRNA

NCBI chr 1:176,716,420...176,726,400
Ensembl chr 1:176,716,420...176,726,400

G

polo-like kinase 2

increases expression

Etoposide results in increased expression of PLK2 mRNA

NCBI chr 2:41,969,176...41,974,945
Ensembl chr 2:41,969,176...41,974,947

G

polo-like kinase 3

increases expression

Etoposide results in increased expression of PLK3 mRNA

NCBI chr 5:130,607,142...130,612,317
Ensembl chr 5:130,607,142...130,612,317

G

proteolipid protein 1

affects response to substance

PLP1 protein affects the susceptibility to Etoposide

NCBI chr X:100,184,039...100,201,035
Ensembl chr X:100,185,767...100,201,032

G

phospholipid phosphatase 2

decreases expression

Etoposide results in decreased expression of PLPP2 mRNA

NCBI chr 7:10,175,918...10,184,032
Ensembl chr 7:10,175,948...10,184,071

G

peptidase M20 domain containing 1

increases expression

Etoposide results in increased expression of PM20D1 mRNA

NCBI chr13:43,237,954...43,259,999
Ensembl chr13:43,237,971...43,259,999

G

phorbol-12-myristate-13-acetate-induced protein 1

increases expression

Etoposide results in increased expression of PMAIP1 mRNA

NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429

G

premelanosome protein

affects response to substance

PMEL protein affects the susceptibility to Etoposide

NCBI chr 7:1,138,202...1,148,735
Ensembl chr 7:1,138,586...1,148,746

G

peripheral myelin protein 2

affects response to substance

PMP2 protein affects the susceptibility to Etoposide

NCBI chr 2:91,611,334...91,615,252
Ensembl chr 2:91,611,334...91,615,252

G

peripheral myelin protein 22

affects response to substance

PMP22 protein affects the susceptibility to Etoposide

NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714

G

DNA polymerase theta

decreases response to substance

POLQ results in decreased susceptibility to Etoposide

NCBI chr11:63,673,796...63,775,905
Ensembl chr11:63,673,816...63,775,878

G

RNA polymerase I subunit H

decreases response to substance
multiple interactions

POLR1H protein results in decreased susceptibility to Etoposide
Verapamil inhibits the reaction [POLR1H protein results in decreased susceptibility to Etoposide]

NCBI chr20:1,594,936...1,598,854
Ensembl chr20:1,594,936...1,598,854

G

periostin

increases expression

Etoposide results in increased expression of POSTN mRNA

NCBI chr 2:138,527,714...138,559,098
Ensembl chr 2:138,527,696...138,559,099

G

POU class 5 homeobox 1

increases expression

Etoposide results in increased expression of POU5F1 mRNA; Etoposide results in increased expression of POU5F1 protein

NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891

G

PPARG coactivator 1 alpha

increases expression
multiple interactions

Etoposide results in increased expression of PPARGC1A mRNA
Etoposide promotes the reaction [PPARGC1A protein results in increased activity of ESRRA protein]

PMID:26259609 PMID:30818834

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

PPARG coactivator 1 beta

increases expression

Etoposide results in increased expression of PPARGC1B mRNA

NCBI chr18:54,758,891...54,861,103
Ensembl chr18:54,758,902...54,861,194

G

protein phosphatase, Mg2+/Mn2+ dependent, 1D

increases expression

Etoposide results in increased expression of PPM1D protein

NCBI chr10:70,172,603...70,208,607
Ensembl chr10:70,172,603...70,208,607

G

protein phosphatase 1, regulatory subunit 13 like

increases expression
multiple interactions
decreases response to substance

Etoposide results in increased expression of PPP1R13L mRNA
Etoposide results in increased expression of and results in increased localization of PPP1R13L protein
PPP1R13L results in decreased susceptibility to Etoposide

PMID:17570360 PMID:19299014

NCBI chr 1:79,010,997...79,030,714
Ensembl chr 1:79,011,745...79,030,712

G

protein regulator of cytokinesis 1

decreases expression

Etoposide results in decreased expression of PRC1 mRNA

NCBI chr 1:134,250,086...134,271,765
Ensembl chr 1:134,250,081...134,271,765

G

peroxiredoxin 1

decreases expression

Etoposide results in decreased expression of PRDX1 protein

NCBI chr 5:130,147,258...130,162,856
Ensembl chr 5:130,147,204...130,162,856

G

protein kinase AMP-activated non-catalytic subunit beta 1

increases expression

Etoposide results in increased expression of PRKAB1 mRNA

NCBI chr12:40,588,140...40,598,673
Ensembl chr12:40,588,211...40,598,661

G

protein kinase C, delta

multiple interactions

Etoposide results in increased cleavage of and results in increased activity of PRKCD protein

NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352

G

protein kinase C, zeta

increases response to substance

PRKCZ protein results in increased susceptibility to Etoposide

NCBI chr 5:165,817,786...165,930,386
Ensembl chr 5:165,819,466...165,930,367

G

protein kinase, DNA-activated, catalytic subunit

increases phosphorylation
multiple interactions

Etoposide results in increased phosphorylation of PRKDC protein
PRKDC protein promotes the reaction [Etoposide results in increased phosphorylation of SP1 protein]

NCBI chr11:85,040,790...85,258,357
Ensembl chr11:85,040,792...85,257,952

G

protein kinase cAMP-dependent X-linked catalytic subunit

increases expression

Etoposide results in increased expression of PRKX mRNA

NCBI chr X:41,823,349...41,866,844
Ensembl chr X:41,823,355...41,866,669

G

prion protein

decreases response to substance

PRNP protein results in decreased susceptibility to Etoposide

NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937

G

protein C receptor

increases expression

Etoposide results in increased expression of PROCR mRNA

NCBI chr 3:144,254,596...144,258,863
Ensembl chr 3:144,254,380...144,258,903

G

proteasome 26S subunit, non-ATPase 13

multiple interactions

[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of PSMD13 protein

NCBI chr 1:195,964,617...195,976,895
Ensembl chr 1:195,964,138...195,976,905

G

phosphatase and tensin homolog

multiple interactions
increases response to substance

PTEN protein inhibits the reaction [Etoposide results in increased phosphorylation of and results in increased activity of AKT1 protein]; PTEN protein modified form promotes the reaction [Etoposide results in increased cleavage of PARP1 protein]; PTEN protein promotes the reaction [Etoposide results in increased cleavage of PARP1 protein]; Wortmannin inhibits the reaction [PTEN protein results in increased susceptibility to Etoposide]

PMID:16807353 PMID:17935137

NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838

G

prostaglandin-endoperoxide synthase 2

increases expression
multiple interactions

Etoposide results in increased expression of PTGS2 protein
PTGS2 mutant form inhibits the reaction [VEGFC protein results in decreased susceptibility to Etoposide]

PMID:24184161 PMID:26259609

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

pseudouridine synthase 3

decreases expression

Etoposide results in decreased expression of PUS3 mRNA

NCBI chr 8:33,910,461...33,918,716
Ensembl chr 8:33,911,357...33,918,714

G

glycogen phosphorylase, muscle associated

decreases expression

Etoposide results in decreased expression of PYGM mRNA

NCBI chr 1:203,690,550...203,705,369
Ensembl chr 1:203,690,533...203,705,368

G

RAB17, member RAS oncogene family

affects response to substance

RAB17 protein affects the susceptibility to Etoposide

NCBI chr 9:91,552,924...91,566,759
Ensembl chr 9:91,553,464...91,566,451

G

RAB20, member RAS oncogene family

affects response to substance

RAB20 protein affects the susceptibility to Etoposide

NCBI chr16:78,019,337...78,043,529
Ensembl chr16:78,019,337...78,043,529

G

RAD51 recombinase

affects localization

Etoposide affects the localization of RAD51 protein

NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035

G

RAD52 homolog, DNA repair protein

multiple interactions
increases expression

BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of RAD52 protein]
Etoposide results in increased expression of RAD52 mRNA; Etoposide results in increased expression of RAD52 protein

PMID:16417649 PMID:19799994

NCBI chr 4:153,106,062...153,128,598
Ensembl chr 4:153,106,062...153,128,207

G

RAD54 homolog B

multiple interactions

RAD54B protein affects the reaction [Etoposide results in increased expression of H2AX protein]

NCBI chr 5:25,032,112...25,104,630
Ensembl chr 5:25,032,066...25,104,616

G

RAD54 like

multiple interactions
increases expression

BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of RAD54L protein]

NCBI chr 5:129,575,431...129,605,100
Ensembl chr 5:129,575,378...129,605,070

G

Ras interacting protein 1

affects response to substance

RASIP1 protein affects the susceptibility to Etoposide

NCBI chr 1:96,097,135...96,109,564
Ensembl chr 1:96,091,074...96,109,562

G

Ras association domain family member 1

multiple interactions
increases response to substance

[RASSF1 co-treated with Etoposide] affects the folding of and results in increased activity of BAX protein; [RASSF1 co-treated with Etoposide] results in increased cleavage of CASP3 protein; [RASSF1 co-treated with Etoposide] results in increased expression of CDKN1A protein; ABT-737 promotes the reaction [RASSF1 results in increased susceptibility to Etoposide]

NCBI chr 8:108,225,023...108,236,164
Ensembl chr 8:108,225,023...108,236,164

G

RB transcriptional corepressor 1

affects response to substance
decreases phosphorylation
multiple interactions

RB1 protein affects the susceptibility to Etoposide
Etoposide results in decreased phosphorylation of RB1 protein
[Colforsin co-treated with Theophylline] inhibits the reaction [Etoposide results in decreased phosphorylation of RB1 protein]

PMID:9454737 PMID:17640669

NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302

G

RNA binding motif protein 17

decreases response to substance

RBM17 protein results in decreased susceptibility to Etoposide

NCBI chr17:66,937,140...66,954,034
Ensembl chr17:66,937,140...66,954,014

G

RNA binding motif protein 34

decreases expression

Etoposide results in decreased expression of RBM34 mRNA

NCBI chr19:54,936,516...54,956,810
Ensembl chr19:54,936,531...54,956,715

G

regulator of calcineurin 1

affects response to substance

RCAN1 protein affects the susceptibility to Etoposide

NCBI chr11:31,622,208...31,702,150
Ensembl chr11:31,622,210...31,702,045

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

retinol saturase

increases expression

Etoposide results in increased expression of RETSAT mRNA

NCBI chr 4:104,653,306...104,662,069
Ensembl chr 4:104,653,155...104,668,310

G

replication factor C subunit 1

decreases expression

Etoposide results in decreased expression of RFC1 mRNA

NCBI chr14:42,966,279...43,041,372
Ensembl chr14:42,966,324...43,041,370

G

regulator of cell cycle

increases expression

Etoposide results in increased expression of RGCC mRNA

NCBI chr15:54,662,483...54,675,320
Ensembl chr15:54,662,483...54,681,141

G

receptor-interacting serine-threonine kinase 2

multiple interactions
increases expression

Estradiol inhibits the reaction [Etoposide results in increased expression of RIPK2 mRNA]

NCBI chr 5:29,630,806...29,662,804
Ensembl chr 5:29,631,570...29,662,657

G

ripply transcriptional repressor 3

increases expression

Etoposide results in increased expression of RIPPLY3 mRNA

NCBI chr11:33,648,471...33,656,587
Ensembl chr11:33,648,486...33,656,584

G

ring finger protein 113A1

decreases expression

Etoposide results in decreased expression of RNF113A mRNA

NCBI chr X:116,427,941...116,429,164
Ensembl chr X:116,427,684...116,433,762

G

roundabout guidance receptor 1

affects response to substance

ROBO1 protein affects the susceptibility to Etoposide

NCBI chr11:10,580,863...11,621,675
Ensembl chr11:10,580,908...11,620,203

G

roundabout guidance receptor 3

increases expression

Etoposide results in increased expression of ROBO3 mRNA

NCBI chr 8:37,133,542...37,151,674
Ensembl chr 8:37,133,916...37,151,315

G

rhophilin associated tail protein 1

affects response to substance

ROPN1 protein affects the susceptibility to Etoposide

NCBI chr11:66,097,854...66,127,148
Ensembl chr11:66,097,856...66,127,148

G

ribosomal protein L6

decreases response to substance

RPL6 protein results in decreased susceptibility to Etoposide

NCBI chr12:35,347,493...35,352,011
Ensembl chr12:35,347,497...35,351,921

G

ribosomal protein S27-like

increases expression

Etoposide results in increased expression of RPS27L protein

NCBI chr 8:67,562,483...67,567,418
Ensembl chr 8:67,562,483...67,567,418

G

ribosomal protein S6

increases phosphorylation

Etoposide results in increased phosphorylation of RPS6 protein

NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602

G

RAS related

increases expression

Etoposide results in increased expression of RRAS mRNA

NCBI chr 1:95,500,582...95,504,362
Ensembl chr 1:95,500,566...95,504,357

G

ribonucleotide reductase regulatory TP53 inducible subunit M2B

increases expression

Etoposide results in increased expression of RRM2B mRNA

NCBI chr 7:69,077,024...69,108,742
Ensembl chr 7:69,078,291...69,108,633

G

RT1 class Ia, locus A2

affects expression

Etoposide affects the expression of HLA-E mRNA

NCBI chr20:4,870,939...4,910,183

G

RT1 class I, locus CE16

affects expression

Etoposide affects the expression of HLA-A mRNA

NCBI chr20:3,257,109...3,260,747
Ensembl chr20:3,257,123...3,279,563

G

rhotekin

increases expression

Etoposide results in increased expression of RTKN mRNA

NCBI chr 4:115,640,813...115,657,952
Ensembl chr 4:115,640,774...115,657,952

G

RUNX family transcription factor 1

increases mutagenesis
increases response to substance

Etoposide results in increased mutagenesis of RUNX1 gene
RUNX1 gene mutant form results in increased susceptibility to Etoposide

PMID:15217836 PMID:28624474

NCBI chr11:31,839,880...32,074,427
Ensembl chr11:31,843,764...32,074,542

G

RUNX family transcription factor 3

increases response to substance

RUNX3 protein results in increased susceptibility to Etoposide

NCBI chr 5:147,360,587...147,419,161
Ensembl chr 5:147,360,994...147,419,156

G

retinoid X receptor alpha

multiple interactions

Etoposide promotes the reaction [RXRA protein results in increased expression of CETP mRNA]; Tretinoin promotes the reaction [Etoposide promotes the reaction [RXRA protein results in increased expression of CETP mRNA]]

NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712

G

ryanodine receptor 2

decreases expression

Etoposide results in decreased expression of RYR2 mRNA

NCBI chr17:58,389,925...58,975,641
Ensembl chr17:58,389,925...58,975,142

G

sodium voltage-gated channel beta subunit 3

increases expression

Etoposide results in increased expression of SCN3B mRNA

NCBI chr 8:40,630,372...40,652,869
Ensembl chr 8:40,630,455...40,652,868

G

sodium voltage-gated channel beta subunit 4

increases expression

Etoposide results in increased expression of SCN4B mRNA

NCBI chr 8:45,446,580...45,462,294
Ensembl chr 8:45,446,215...45,462,292

G

syndecan 1

increases expression

Etoposide results in increased expression of SDC1 mRNA

NCBI chr 6:31,562,799...31,585,267
Ensembl chr 6:31,562,739...31,585,264

G

succinate dehydrogenase complex assembly factor 1

decreases expression

Etoposide results in decreased expression of SDHAF1 mRNA

NCBI chr 1:85,576,207...85,577,156
Ensembl chr 1:85,576,041...85,577,366
Ensembl chr 1:85,576,041...85,577,366

G

serpin family E member 2

increases expression

Etoposide results in increased expression of SERPINE2 mRNA

NCBI chr 9:81,124,746...81,188,866
Ensembl chr 9:81,124,804...81,188,826

G

sestrin 1

increases expression

Etoposide results in increased expression of SESN1 mRNA

NCBI chr20:45,294,876...45,387,698
Ensembl chr20:45,294,871...45,387,697

G

stratifin

increases expression

Etoposide results in increased expression of SFN mRNA

NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314

G

stem-loop histone mRNA binding protein

decreases expression

Etoposide results in decreased expression of SLBP mRNA

NCBI chr14:77,071,441...77,081,911
Ensembl chr14:77,071,632...77,081,906

G

solute carrier family 16, member 6

affects response to substance

SLC16A6 protein affects the susceptibility to Etoposide

NCBI chr10:94,424,377...94,447,482
Ensembl chr10:94,426,244...94,448,779

G

solute carrier family 1 member 5

decreases expression

Etoposide results in decreased expression of SLC1A5 mRNA

NCBI chr 1:77,456,849...77,470,952
Ensembl chr 1:77,456,694...77,470,952

G

solute carrier family 22, member 18

affects response to substance

SLC22A18 protein affects the susceptibility to Etoposide

NCBI chr 1:198,670,626...198,694,977
Ensembl chr 1:198,671,731...198,694,975

G

solute carrier family 27 member 3

affects response to substance

SLC27A3 protein affects the susceptibility to Etoposide

NCBI chr 2:175,853,241...175,857,909
Ensembl chr 2:175,853,241...175,857,909

G

solute carrier family 2 member 6

increases expression

Etoposide results in increased expression of SLC2A6 mRNA

NCBI chr 3:10,348,395...10,355,208
Ensembl chr 3:10,348,395...10,355,208

G

solute carrier family 35, member F2

decreases expression

Etoposide results in decreased expression of SLC35F2 mRNA

NCBI chr 8:54,159,970...54,203,614
Ensembl chr 8:54,159,970...54,203,612

G

solute carrier family 45, member 3

multiple interactions

Etoposide inhibits the reaction [Dihydrotestosterone results in increased expression of SLC45A3 mRNA]

NCBI chr13:43,407,293...43,427,588
Ensembl chr13:43,407,293...43,427,588

G

solute carrier family 4 member 11

increases expression

Etoposide results in increased expression of SLC4A11 mRNA

NCBI chr 3:117,900,223...117,912,787
Ensembl chr 3:117,900,223...117,912,674

G

solute carrier family 7 member 11

affects response to substance

SLC7A11 protein affects the susceptibility to Etoposide

NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536

G

solute carrier family 7 member 3

decreases expression

Etoposide results in decreased expression of SLC7A3 mRNA

NCBI chr X:66,210,071...66,216,482
Ensembl chr X:66,210,081...66,215,708

G

solute carrier family 7 member 5

affects response to substance

SLC7A5 protein affects the susceptibility to Etoposide

NCBI chr19:49,935,220...49,963,823
Ensembl chr19:49,935,220...49,963,823

G

solute carrier family 8 member A1

decreases expression

Etoposide results in decreased expression of SLC8A1 mRNA

NCBI chr 6:13,194,609...13,547,369
Ensembl chr 6:13,194,662...13,535,628

G

solute carrier organic anion transporter family, member 2b1

multiple interactions

Etoposide inhibits the reaction [SLCO2B1 protein results in increased uptake of Cascade Blue]

NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353

G

SMAD family member 2

multiple interactions
increases phosphorylation

4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Etoposide results in increased phosphorylation of SMAD2 protein]

NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323

G

sphingomyelin phosphodiesterase, acid-like 3A

affects response to substance

SMPDL3A protein affects the susceptibility to Etoposide

NCBI chr20:37,132,592...37,155,567
Ensembl chr20:37,132,592...37,155,567

G

superoxide dismutase 2

increases expression
decreases response to substance

Etoposide results in increased expression of SOD2 protein
SOD2 protein results in decreased susceptibility to Etoposide

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

spermatogenesis and oogenesis specific basic helix-loop-helix 1

decreases expression

Etoposide results in decreased expression of SOHLH1 mRNA

NCBI chr 3:8,662,995...8,667,521
Ensembl chr 3:8,663,318...8,667,388

G

sorbin and SH3 domain containing 1

affects response to substance

SORBS1 protein affects the susceptibility to Etoposide

NCBI chr 1:239,107,882...239,330,276
Ensembl chr 1:239,108,777...239,330,169

G

sorbin and SH3 domain containing 2

affects response to substance

SORBS2 protein affects the susceptibility to Etoposide

NCBI chr16:46,435,220...46,748,743
Ensembl chr16:46,435,237...46,626,514

G

sortilin 1

affects response to substance

SORT1 protein affects the susceptibility to Etoposide

NCBI chr 2:195,924,033...196,002,354
Ensembl chr 2:195,924,099...196,002,354

G

SRY-box transcription factor 10

affects response to substance

SOX10 protein affects the susceptibility to Etoposide

NCBI chr 7:110,725,274...110,734,651
Ensembl chr 7:110,725,274...110,735,544

G

SRY-box transcription factor 2

multiple interactions

FTL protein affects the reaction [Etoposide results in increased expression of SOX2 protein]

NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338

G

Sp1 transcription factor

increases phosphorylation
increases expression
increases activity
multiple interactions

Etoposide results in increased phosphorylation of SP1 protein
Etoposide results in increased expression of SP1 mRNA
Etoposide results in increased activity of SP1 protein
cordycepin inhibits the reaction [Etoposide results in increased activity of SP1 protein]; cordycepin inhibits the reaction [Etoposide results in increased expression of SP1 mRNA]
PRKDC protein promotes the reaction [Etoposide results in increased phosphorylation of SP1 protein]; wortmannin inhibits the reaction [Etoposide results in increased phosphorylation of SP1 protein]

PMID:17441964 PMID:23690541

NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961

G

spermatogenesis associated 18

increases expression

Etoposide results in increased expression of SPATA18 mRNA

PMID:21527772 PMID:29397400

NCBI chr14:34,531,931...34,558,671
Ensembl chr14:34,531,061...34,558,687

G

secreted phosphoprotein 1

affects response to substance
decreases expression

SPP1 protein affects the susceptibility to Etoposide
Etoposide results in decreased expression of SPP1 mRNA

PMID:16217747 PMID:25270620

NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162

G

serine palmitoyltransferase, small subunit A

affects response to substance

SPTSSA protein affects the susceptibility to Etoposide

NCBI chr 6:72,144,714...72,156,130
Ensembl chr 6:72,144,714...72,156,214

G

sulfiredoxin 1

increases expression
multiple interactions

Etoposide results in increased expression of SRXN1 mRNA; Etoposide results in increased expression of SRXN1 protein
NFE2L2 protein affects the reaction [Etoposide results in increased expression of SRXN1 protein]; TP53 protein affects the reaction [Etoposide results in increased expression of SRXN1 protein]

PMID:22003191 PMID:27358234 PMID:27982581

NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448

G

ST3 beta-galactoside alpha-2,3-sialyltransferase 5

decreases response to substance

ST3GAL5 protein results in decreased susceptibility to Etoposide

NCBI chr 4:104,134,613...104,192,558
Ensembl chr 4:104,134,613...104,192,558

G

ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2

affects response to substance

ST6GALNAC2 protein affects the susceptibility to Etoposide

NCBI chr10:101,910,220...101,928,412
Ensembl chr10:101,909,971...101,915,008
Ensembl chr10:101,909,971...101,915,008

G

suppression of tumorigenicity 7

affects response to substance

ST7 protein affects the susceptibility to Etoposide

NCBI chr 4:46,041,655...46,289,745
Ensembl chr 4:46,042,236...46,289,740

G

signal transducer and activator of transcription 1

multiple interactions

[STAT1 protein results in increased activity of CASP3 protein] which results in increased susceptibility to Etoposide; [STAT1 protein results in increased activity of CASP7 protein] which results in increased susceptibility to Etoposide

NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540

G

stanniocalcin 1

increases expression

Etoposide results in increased expression of STC1 mRNA

NCBI chr15:44,299,591...44,311,695
Ensembl chr15:44,299,621...44,310,264

G

stress-induced phosphoprotein 1

increases expression

Etoposide results in increased expression of STIP1 protein

NCBI chr 1:204,209,433...204,228,452
Ensembl chr 1:204,178,932...204,228,476

G

stathmin 1

affects response to substance

STMN1 affects the susceptibility to Etoposide

NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154

G

stathmin 2

decreases expression

Etoposide results in decreased expression of STMN2 mRNA

NCBI chr 2:93,204,690...93,252,011
Ensembl chr 2:93,204,692...93,252,011

G

stomatin

increases expression

Etoposide results in increased expression of STOM mRNA

NCBI chr 3:18,645,058...18,667,343
Ensembl chr 3:18,644,378...18,667,354

G

synaptotagmin-like 1

increases expression

Etoposide results in increased expression of SYTL1 mRNA

NCBI chr 5:145,452,524...145,462,940
Ensembl chr 5:145,422,669...145,462,940

G

transporter 1, ATP binding cassette subfamily B member

increases expression

Etoposide results in increased expression of TAP1 mRNA

PMID:17374387 PMID:21527772

NCBI chr20:4,656,262...4,666,634
Ensembl chr20:4,656,263...4,666,901

G

Tax1 binding protein 3

increases expression

Etoposide results in increased expression of TAX1BP3 mRNA

NCBI chr10:57,795,845...57,800,363
Ensembl chr10:57,795,382...57,800,363

G

TBC1 domain family, member 8

increases expression

Etoposide results in increased expression of TBC1D8 mRNA

NCBI chr 9:41,651,394...41,761,432
Ensembl chr 9:41,651,395...41,761,409

G

transducin (beta)-like 1 X-linked

decreases expression

Etoposide results in decreased expression of TBL1X mRNA

NCBI chr X:41,574,558...41,731,117
Ensembl chr X:41,576,047...41,731,101

G

TATA-box binding protein like 1

affects localization

Etoposide affects the localization of TBPL1 protein

NCBI chr 1:22,777,892...22,803,305
Ensembl chr 1:22,778,459...22,803,122
Ensembl chr 1:22,778,459...22,803,122

G

titin-cap

decreases expression

Etoposide results in decreased expression of TCAP mRNA

NCBI chr10:83,381,719...83,382,887
Ensembl chr10:83,381,719...83,382,887

G

transcription factor like 5

affects response to substance

TCFL5 protein affects the susceptibility to Etoposide

NCBI chr 3:167,734,471...167,754,174
Ensembl chr 3:167,734,473...167,754,282

G

t-complex 1

multiple interactions

[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of TCP1 protein

NCBI chr 1:47,829,061...47,836,809
Ensembl chr 1:47,828,652...47,836,839

G

tudor domain containing 3

affects response to substance

TDRD3 protein affects the susceptibility to Etoposide

NCBI chr15:63,340,531...63,497,208
Ensembl chr15:63,341,235...63,476,110

G

terminal nucleotidyltransferase 5A

affects response to substance

TENT5A protein affects the susceptibility to Etoposide

NCBI chr 8:86,222,294...86,229,045
Ensembl chr 8:86,225,357...86,229,045

G

testis expressed 264

decreases expression

Etoposide results in decreased expression of TEX264 mRNA

NCBI chr 8:107,295,806...107,322,858
Ensembl chr 8:107,295,806...107,323,232

G

transcription factor A, mitochondrial

increases expression

Etoposide results in increased expression of TFAM mRNA

NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292

G

transcription factor AP-2 alpha

affects response to substance
increases response to substance

TFAP2A protein affects the susceptibility to Etoposide
TFAP2A protein results in increased susceptibility to Etoposide

PMID:16204029 PMID:16217747

NCBI chr17:24,028,716...24,047,507
Ensembl chr17:24,024,432...24,047,507

G

transcription factor EC

decreases expression

Etoposide results in decreased expression of TFEC mRNA

NCBI chr 4:45,106,129...45,180,236
Ensembl chr 4:45,107,641...45,180,236

G

trefoil factor 3

affects response to substance

TFF3 protein affects the susceptibility to Etoposide

NCBI chr20:9,193,259...9,197,969
Ensembl chr20:9,193,262...9,198,054

G

tissue factor pathway inhibitor

affects response to substance

TFPI protein affects the susceptibility to Etoposide

NCBI chr 3:69,533,156...69,582,547
Ensembl chr 3:69,533,156...69,576,880

G

tissue factor pathway inhibitor 2

affects response to substance

TFPI2 protein affects the susceptibility to Etoposide

NCBI chr 4:31,981,786...31,986,707
Ensembl chr 4:31,982,178...31,986,600

G

transferrin receptor

multiple interactions
decreases expression

1-cyclopropyl-4-(4-((5-methyl-3-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)pyridin-2-yl)piperazine inhibits the reaction [Etoposide results in decreased expression of TFRC protein]
Etoposide results in decreased expression of TFRC mRNA; Etoposide results in decreased expression of TFRC protein

NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257

G

TDP-glucose 4,6-dehydratase

affects response to substance

TGDS protein affects the susceptibility to Etoposide

NCBI chr15:95,175,064...95,195,555
Ensembl chr15:95,174,608...95,195,554

G

transforming growth factor alpha

increases expression

Etoposide results in increased expression of TGFA mRNA

NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894

G

TGFB-induced factor homeobox 2

decreases expression

Etoposide results in decreased expression of TGIF2 mRNA

NCBI chr 3:145,333,152...145,348,599
Ensembl chr 3:145,333,418...145,348,596

G

thrombospondin 4

increases expression

Etoposide results in increased expression of THBS4 mRNA

NCBI chr 2:23,983,158...24,025,289
Ensembl chr 2:23,983,158...24,026,313

G

timeless interacting protein

decreases expression

Etoposide results in decreased expression of TIPIN mRNA

NCBI chr 8:64,780,813...64,801,358
Ensembl chr 8:64,780,828...64,801,352

G

transmembrane 7 superfamily member 3

increases expression

Etoposide results in increased expression of TM7SF3 mRNA

NCBI chr 4:179,518,127...179,550,154
Ensembl chr 4:179,518,130...179,550,154

G

transmembrane BAX inhibitor motif containing 4

increases expression

Etoposide results in increased expression of TMBIM4 mRNA

NCBI chr 7:55,718,690...55,733,277
Ensembl chr 7:55,718,699...55,742,773

G

transmembrane channel like 6

affects response to substance

TMC6 protein affects the susceptibility to Etoposide

NCBI chr10:102,982,059...102,999,509
Ensembl chr10:102,971,229...102,998,960

G

transmembrane protein 185B

decreases expression

Etoposide results in decreased expression of TMEM185B mRNA

NCBI chr13:30,647,533...30,650,864
Ensembl chr13:30,647,482...30,650,858

G

transmembrane protein 204

decreases expression

Etoposide results in decreased expression of TMEM204 mRNA

NCBI chr10:14,076,518...14,104,849
Ensembl chr10:14,076,519...14,101,920

G

transmembrane protein 47

affects response to substance

TMEM47 protein affects the susceptibility to Etoposide

NCBI chr X:45,421,405...45,447,900
Ensembl chr X:45,421,405...45,447,900

G

transmembrane protein 97

affects response to substance

TMEM97 protein affects the susceptibility to Etoposide

NCBI chr10:63,438,228...63,447,311
Ensembl chr10:63,438,222...63,589,730

G

thymosin beta 4, X-linked

decreases response to substance
multiple interactions

TMSB4X protein results in decreased susceptibility to Etoposide
TMSB4X protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; TMSB4X protein inhibits the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]

NCBI chr X:27,144,666...27,146,667
Ensembl chr X:27,128,610...27,146,667

G

tumor necrosis factor

increases expression

Etoposide results in increased expression of TNF mRNA

PMID:15135310 PMID:18523641

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor superfamily member 11B

increases expression

Etoposide results in increased expression of TNFRSF11B mRNA

NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538

G

TNF receptor superfamily member 12A

multiple interactions
increases expression

Estradiol inhibits the reaction [Etoposide results in increased expression of TNFRSF12A mRNA]

NCBI chr10:12,707,077...12,709,071
Ensembl chr10:12,689,890...12,709,045

G

TNF receptor superfamily member 14

increases expression

Etoposide results in increased expression of TNFRSF14 mRNA

NCBI chr 5:165,486,069...165,494,421
Ensembl chr 5:165,484,262...165,493,703

G

TNF receptor superfamily member 1A

affects response to substance

TNFRSF1A protein affects the susceptibility to Etoposide

NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591

G

TNF superfamily member 11

decreases expression

Etoposide results in decreased expression of TNFSF11 mRNA

NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445

G

TNF superfamily member 9

increases expression

Etoposide results in increased expression of TNFSF9 mRNA

NCBI chr 9:1,944,017...1,946,351
Ensembl chr 9:1,944,017...1,946,345

G

tankyrase

affects response to substance

TNKS protein affects the susceptibility to Etoposide

NCBI chr16:57,223,174...57,370,740
Ensembl chr16:57,225,094...57,366,260

G

DNA topoisomerase II alpha

affects binding
decreases activity
multiple interactions
affects activity
decreases expression
increases response to substance
affects response to substance
decreases response to substance

Etoposide binds to TOP2A protein
Etoposide analog results in decreased activity of TOP2A protein; Etoposide metabolite results in decreased activity of TOP2A protein; Etoposide results in decreased activity of TOP2A protein
[Ciprofloxacin binds to TOP2A protein] inhibits the reaction [Etoposide binds to TOP2A protein]; [EGF protein results in decreased expression of TOP2A protein] which results in decreased susceptibility to Etoposide; [MAPK12 protein results in increased phosphorylation of TOP2A protein] which results in increased susceptibility to Etoposide; [MAPK12 protein results in increased stability of TOP2A protein] which results in increased susceptibility to Etoposide; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Etoposide promotes the reaction [MDM2 protein binds to TOP2A protein]]; delphinidin results in decreased susceptibility to [Etoposide affects the activity of TOP2A protein]; Etoposide metabolite inhibits the reaction [TOP2A protein binds to Nucleic Acids, Nucleotides, and Nucleosides]; Etoposide metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]; Etoposide promotes the reaction [MDM2 protein binds to TOP2A protein]; TOP2A results in decreased susceptibility to [Carboplatin co-treated with Etoposide co-treated with Ifosfamide]; TOP2A results in decreased susceptibility to [Cisplatin co-treated with Etoposide]
Etoposide results in decreased expression of TOP2A protein
TOP2A protein results in increased susceptibility to Etoposide
TOP2A protein modified form affects the susceptibility to Etoposide
TOP2A gene mutant form results in decreased susceptibility to Etoposide; TOP2A protein mutant form results in decreased susceptibility to Etoposide

PMID:10856430 PMID:11325482 PMID:11470519 PMID:11531262 PMID:11676865 More...

NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874

G

DNA topoisomerase II beta

decreases response to substance
decreases activity
affects response to substance
decreases expression
multiple interactions
increases response to substance

TOP2B protein mutant form results in decreased susceptibility to Etoposide
Etoposide results in decreased activity of TOP2B protein
TOP2B protein affects the susceptibility to Etoposide
Etoposide results in decreased expression of TOP2B protein
TOP2B protein affects the reaction [Etoposide results in increased expression of H2AX protein]
TOP2B protein mutant form results in increased susceptibility to Etoposide

PMID:10856430 PMID:15322234 PMID:16239602 PMID:17875725 PMID:26198043 More...

NCBI chr15:9,051,340...9,111,721
Ensembl chr15:9,051,341...9,112,085

G

DNA topoisomerase III alpha

decreases expression

Etoposide results in decreased expression of TOP3A mRNA

NCBI chr10:45,419,219...45,457,356
Ensembl chr10:45,419,217...45,457,559

G

torsin family 1, member A

decreases expression

Etoposide results in decreased expression of TOR1A mRNA

NCBI chr 3:14,250,667...14,257,704
Ensembl chr 3:14,250,676...14,257,691

G

tumor protein p53

increases acetylation
affects activity
increases expression
multiple interactions
increases activity
increases phosphorylation
affects response to substance
increases response to substance

Etoposide results in increased acetylation of TP53 protein; Etoposide results in increased acetylation of TP53 protein mutant form
Etoposide affects the activity of TP53 protein; Etoposide metabolite affects the activity of TP53 protein
Etoposide results in increased expression of TRP53 protein
[CDKN2A gene mutant form results in increased expression of CDKN2A protein alternative form] inhibits the reaction [Etoposide results in increased expression of TRP53 protein]; Etoposide results in increased phosphorylation of and results in increased activity of TRP53 protein; TRP53 affects the reaction [Etoposide results in increased expression of CDKN1A mRNA]; TRP53 affects the reaction [Etoposide results in increased expression of TPT1 mRNA]; TRP53 affects the reaction [Etoposide results in increased expression of TPT1 protein]; TRP53 protein affects the reaction [Etoposide results in increased expression of BTG2 mRNA]
Etoposide results in increased activity of TP53 protein
Etoposide results in increased phosphorylation of TP53 protein
TRP53 protein affects the susceptibility to Etoposide
Etoposide results in increased expression of TP53 protein
[Etoposide results in increased expression of TP53 protein] which results in increased expression of GDF15 protein; Etoposide results in increased expression of TP53 protein
2,4,4'-trichlorobiphenyl inhibits the reaction [Etoposide results in increased expression of TP53 protein]; 2,4,5,2',5'-pentachlorobiphenyl inhibits the reaction [Etoposide results in increased expression of TP53 protein]; 3,4,5,3',4'-pentachlorobiphenyl inhibits the reaction [Etoposide results in increased expression of TP53 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of CASP3 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of PARP1 protein]; [CASP8 co-treated with TP53] inhibits the reaction [CASP8 protein mutant form results in decreased susceptibility to Etoposide]; [Doxorubicin co-treated with Vincristine co-treated with Etoposide co-treated with Mitotane] results in decreased expression of TP53 protein; [Etoposide results in increased acetylation of TP53 protein mutant form] which results in increased expression of UBE2C protein; [TP53 protein results in increased susceptibility to Etoposide] which results in decreased chemical synthesis of benzo(a)pyrene 7,8-dihydrodiol; Cadmium Chloride affects the reaction [Etoposide results in increased phosphorylation of TP53 protein]; DAPK1 protein promotes the reaction [Etoposide results in increased expression of TP53 protein modified form]; DAPK1 protein promotes the reaction [Etoposide results in increased expression of TP53 protein]; entinostat promotes the reaction [Etoposide results in increased expression of and results in increased acetylation of TP53 protein]; Etoposide promotes the reaction [[TP53 protein binds to GDF15 promoter] which results in increased expression of GDF15 mRNA]; Etoposide promotes the reaction [entinostat results in increased expression of TP53 protein]; Etoposide promotes the reaction [TP53 protein binds to TNFRSF10B promoter]; Etoposide promotes the reaction [TP53 protein results in increased chemical synthesis of benzo(a)pyrene 7,8-dihydrodiol]; Etoposide promotes the reaction [trichostatin A results in increased expression of TP53 protein]; Etoposide promotes the reaction [UF010 compound results in increased expression of TP53 protein]; Etoposide results in increased expression of and results in increased acetylation of TP53 protein; Etoposide results in increased phosphorylation of and affects the localization of TP53 protein; Etoposide results in increased phosphorylation of and results in increased activity of TP53 protein; NFE2L2 protein affects the reaction [Etoposide results in increased expression of TP53 protein]; NFKB1 protein affects the reaction [Etoposide results in increased expression of TP53 protein]; Oxygen deficiency inhibits the reaction [Etoposide results in increased phosphorylation of TP53 protein]; pifithrin inhibits the reaction [Etoposide results in increased activity of TP53 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased acetylation of TP53 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased phosphorylation of and results in increased activity of TP53 protein]; TP53 affects the reaction [Etoposide results in increased expression of CDKN1A mRNA]; TP53 affects the reaction [Etoposide results in increased expression of TPT1 mRNA]; TP53 promotes the reaction [Etoposide results in increased expression of BTG2 protein]; TP53 promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; TP53 protein affects the reaction [CHEK1 protein affects the susceptibility to Etoposide]; TP53 protein affects the reaction [Etoposide results in decreased expression of UBE2C mRNA]; TP53 protein affects the reaction [Etoposide results in increased expression of SRXN1 protein]; TP53 protein inhibits the reaction [ESR2 protein results in increased susceptibility to Etoposide]; TP53 protein inhibits the reaction [Etoposide results in decreased expression of UBE2C protein]; TP53 protein modified form inhibits the reaction [Etoposide results in increased expression of BBC3 protein]; TP53 protein promotes the reaction [[Etoposide results in increased susceptibility to Benzo(a)pyrene] which results in increased expression of CDKN1A protein]; TP53 protein promotes the reaction [Etoposide promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]]; TP53 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]; TP53 protein promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; TP53 protein promotes the reaction [Etoposide results in increased expression of CYP1A1 protein]; TP53 protein promotes the reaction [Etoposide results in increased expression of ETS1 protein]; trichostatin A promotes the reaction [Etoposide results in increased expression of and results in increased acetylation of TP53 protein]; UF010 compound promotes the reaction [Etoposide results in increased expression of and results in increased acetylation of TP53 protein]
cordycepin promotes the reaction [Etoposide results in increased expression of TP53 protein]; Etoposide promotes the reaction [Acetaminophen results in increased phosphorylation of TP53 protein]; Etoposide results in increased expression of and results in increased phosphorylation of TP53 protein; Niacin deficiency inhibits the reaction [Etoposide results in increased expression of TP53 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased expression of and results in increased phosphorylation of TP53 protein]
TP53 protein results in increased susceptibility to Etoposide; TP53 results in increased susceptibility to Etoposide

PMID:9815696 PMID:11895857 PMID:12082016 PMID:15131059 PMID:15459018 More...

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

tumor protein p53 binding protein 1

increases expression
multiple interactions

Etoposide results in increased expression of TP53BP1 protein
pifithrin inhibits the reaction [Etoposide results in increased expression of and affects the localization of TP53BP1 protein]

PMID:26259609 PMID:27358234

NCBI chr 3:108,166,574...108,270,229
Ensembl chr 3:108,169,980...108,269,822

G

tumor protein p53 inducible protein 3

increases expression

Etoposide results in increased expression of TP53I3 mRNA

NCBI chr 6:27,818,327...27,825,753

G

tumor protein p73

multiple interactions
increases expression

[[Etoposide results in increased expression of TP73 protein] which results in increased expression of VDR protein] which results in increased susceptibility to Calcitriol; TP73 mutant form inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased activity of CASP7 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP8 protein]; TP73 protein affects the reaction [Etoposide results in increased expression of VDR mRNA]
Etoposide results in increased expression of TP73 mRNA; Etoposide results in increased expression of TP73 protein

PMID:17716971 PMID:21801448

NCBI chr 5:164,621,377...164,703,958
Ensembl chr 5:164,621,377...164,681,128

G

triosephosphate isomerase 1

multiple interactions
increases phosphorylation

CDK2 affects the reaction [Etoposide results in increased phosphorylation of TPI1 protein]

NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541

G

tripeptidyl peptidase 2

multiple interactions
affects localization

4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Etoposide affects the localization of TPP2 protein]; SB 203580 inhibits the reaction [Etoposide affects the localization of TPP2 protein]; U 0126 inhibits the reaction [Etoposide affects the localization of TPP2 protein]
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Etoposide affects the localization of TPP2 protein]; Sirolimus promotes the reaction [Etoposide affects the localization of TPP2 protein]; U 0126 inhibits the reaction [Etoposide affects the localization of TPP2 protein]; wortmannin promotes the reaction [Etoposide affects the localization of TPP2 protein]

NCBI chr 9:46,046,712...46,128,157
Ensembl chr 9:46,046,632...46,128,157

G

tumor protein, translationally-controlled 1

increases expression
multiple interactions

Etoposide results in increased expression of TPT1 mRNA
TRP53 affects the reaction [Etoposide results in increased expression of TPT1 mRNA]; TRP53 affects the reaction [Etoposide results in increased expression of TPT1 protein]
Etoposide results in increased expression of TPT1 mRNA; Etoposide results in increased expression of TPT1 protein
TP53 affects the reaction [Etoposide results in increased expression of TPT1 mRNA]

NCBI chr15:51,156,728...51,159,629
Ensembl chr15:51,146,154...51,159,625

G

Tnf receptor-associated factor 2

affects response to substance

TRAF2 protein affects the susceptibility to Etoposide

NCBI chr 3:8,341,950...8,366,609
Ensembl chr 3:8,341,951...8,366,538

G

tribbles pseudokinase 2

affects response to substance

TRIB2 protein affects the susceptibility to Etoposide

NCBI chr 6:38,545,971...38,570,349
Ensembl chr 6:38,545,975...38,569,370

G

tribbles pseudokinase 3

decreases expression

Etoposide results in decreased expression of TRIB3 mRNA

NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497

G

tripartite motif-containing 2

affects response to substance
decreases expression

TRIM2 protein affects the susceptibility to Etoposide
Etoposide results in decreased expression of TRIM2 mRNA

PMID:16217747 PMID:25270620

NCBI chr 2:169,500,628...169,652,855
Ensembl chr 2:169,500,634...169,652,927

G

tripartite motif containing 38

decreases expression

Etoposide results in decreased expression of TRIM38 mRNA

NCBI chr17:41,351,857...41,365,021

G

transient receptor potential cation channel, subfamily V, member 1

increases expression

Etoposide results in increased expression of TRPV1 mRNA

NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513

G

Ttk protein kinase

decreases expression

Etoposide results in decreased expression of TTK mRNA

NCBI chr 8:84,754,329...84,792,653
Ensembl chr 8:84,754,315...84,792,651

G

tubulin, alpha 4A

increases expression

Etoposide results in increased expression of TUBA4A mRNA

NCBI chr 9:76,709,617...76,714,327
Ensembl chr 9:76,709,614...76,713,918

G

Tu translation elongation factor, mitochondrial

decreases expression

Etoposide results in decreased expression of TUFM protein

NCBI chr 1:181,073,788...181,077,395
Ensembl chr 1:181,073,788...181,077,395

G

thioredoxin 2

decreases response to substance

TXN2 protein results in decreased susceptibility to Etoposide

NCBI chr 7:109,496,772...109,510,378
Ensembl chr 7:109,496,761...109,510,359

G

thioredoxin interacting protein

increases expression

Etoposide results in increased expression of TXNIP protein

NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886

G

thioredoxin-like 1

decreases expression

Etoposide results in decreased expression of TXNL1 protein

NCBI chr18:57,125,362...57,155,167
Ensembl chr18:57,125,369...57,165,266

G

thymidylate synthetase

affects response to substance

TYMS gene polymorphism affects the susceptibility to Etoposide

NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536

G

tyrosinase-related protein 1

affects response to substance

TYRP1 protein affects the susceptibility to Etoposide

NCBI chr 5:95,280,982...95,299,516
Ensembl chr 5:95,280,982...95,299,516

G

ubiquitin-conjugating enzyme E2C

decreases expression
multiple interactions

Etoposide results in decreased expression of UBE2C mRNA; Etoposide results in decreased expression of UBE2C protein
[Etoposide results in increased acetylation of TP53 protein mutant form] which results in increased expression of UBE2C protein; CDKN1A protein affects the reaction [Etoposide results in decreased expression of UBE2C protein]; TP53 protein affects the reaction [Etoposide results in decreased expression of UBE2C mRNA]; TP53 protein inhibits the reaction [Etoposide results in decreased expression of UBE2C protein]

PMID:17374387 PMID:27129209

NCBI chr 3:153,506,636...153,509,036
Ensembl chr 3:153,506,636...153,513,339

G

ubiquitin-like 3

affects response to substance

UBL3 protein affects the susceptibility to Etoposide

NCBI chr12:6,473,684...6,518,331
Ensembl chr12:6,473,460...6,518,862

G

uncoupling protein 2

decreases expression

Etoposide results in decreased expression of UCP2 mRNA

NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611

G

UDP glucuronosyltransferase family 1 member A1

affects response to substance
increases glucuronidation

UGT1A1 gene polymorphism affects the susceptibility to Etoposide
UGT1A1 protein results in increased glucuronidation of Etoposide

PMID:12969965 PMID:17151191

NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase 1 family, polypeptide A2

increases glucuronidation

UGT1A3 protein results in increased glucuronidation of Etoposide

NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

unc-5 netrin receptor C

increases response to substance

UNC5C results in increased susceptibility to Etoposide

NCBI chr 2:230,180,353...230,535,219
Ensembl chr 2:230,180,951...230,535,217

G

uridine phosphorylase 2

increases expression

Etoposide results in increased expression of UPP2 mRNA

NCBI chr 3:43,273,048...43,317,417
Ensembl chr 3:43,273,048...43,317,417

G

UTP3, small subunit processome component

decreases expression

Etoposide results in decreased expression of UTP3 mRNA

NCBI chr14:19,515,716...19,517,370
Ensembl chr14:19,515,669...19,517,396

G

vascular cell adhesion molecule 1

multiple interactions
decreases response to substance

[IL4 protein co-treated with VCAM1 protein] inhibits the reaction [Etoposide results in decreased folding of BAX protein]; [VCAM1 protein co-treated with IL4 protein] inhibits the reaction [Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]]; [VCAM1 protein co-treated with IL4 protein] results in decreased susceptibility to Etoposide
VCAM1 protein results in decreased susceptibility to Etoposide

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

G

versican

affects response to substance

VCAN protein affects the susceptibility to Etoposide

NCBI chr 2:20,761,718...20,860,637
Ensembl chr 2:20,761,718...20,860,637

G

voltage-dependent anion channel 1

multiple interactions

Etoposide promotes the reaction [VDAC1 protein binds to VDAC1 protein]

NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640

G

vitamin D receptor

multiple interactions
affects response to substance
increases expression

[[Etoposide results in increased expression of TP73 protein] which results in increased expression of VDR protein] which results in increased susceptibility to Calcitriol; TP73 protein affects the reaction [Etoposide results in increased expression of VDR mRNA]
VDR gene polymorphism affects the susceptibility to Etoposide; VDR intron polymorphism affects the susceptibility to Etoposide

PMID:12969965 PMID:15713801 PMID:17716971

NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677

G

vascular endothelial growth factor A

decreases response to substance

VEGFA mRNA results in decreased susceptibility to Etoposide

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vascular endothelial growth factor C

multiple interactions
decreases response to substance

EDN1 mutant form inhibits the reaction [VEGFC protein results in decreased susceptibility to Etoposide]; PTGS2 mutant form inhibits the reaction [VEGFC protein results in decreased susceptibility to Etoposide]

NCBI chr16:37,712,251...37,827,845
Ensembl chr16:37,712,262...37,827,848

G

vitamin K epoxide reductase complex, subunit 1

increases expression

Etoposide results in increased expression of VKORC1 mRNA

NCBI chr 1:182,502,491...182,505,012
Ensembl chr 1:182,500,844...182,505,008

G

Wnt inhibitory factor 1

increases response to substance

WIF1 protein results in increased susceptibility to Etoposide

NCBI chr 7:56,548,060...56,618,364
Ensembl chr 7:56,548,053...56,618,360

G

WD repeat domain, phosphoinositide interacting 1

affects response to substance

WIPI1 protein affects the susceptibility to Etoposide

NCBI chr10:94,542,946...94,580,174
Ensembl chr10:94,542,946...94,579,846

G

Wnt family member 3A

increases response to substance

WNT3A protein results in increased susceptibility to Etoposide

NCBI chr10:44,034,174...44,078,366
Ensembl chr10:44,034,194...44,078,324

G

WRN RecQ like helicase

increases response to substance

WRN gene mutant form results in increased susceptibility to Etoposide

NCBI chr16:58,763,517...58,898,604
Ensembl chr16:58,763,504...58,895,450

G

XIAP associated factor 1

increases response to substance
increases expression
multiple interactions

XAF1 protein results in increased susceptibility to Etoposide
Etoposide results in increased expression of XAF1 mRNA; Etoposide results in increased expression of XAF1 protein
XAF1 protein affects the reaction [Etoposide results in decreased expression of MT2A protein]; XAF1 protein affects the reaction [Etoposide results in increased cleavage of PARP1 protein]

PMID:15843754 PMID:17570219 PMID:28507149

NCBI chr10:56,917,378...56,929,791
Ensembl chr10:56,917,121...56,929,770

G

X-ray repair cross complementing 1

multiple interactions
affects response to substance
increases expression

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Etoposide results in increased expression of XRCC1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Etoposide results in increased expression of XRCC1 protein]; resveratrol inhibits the reaction [Etoposide results in increased expression of XRCC1 mRNA]; resveratrol inhibits the reaction [Etoposide results in increased expression of XRCC1 protein]; U 0126 inhibits the reaction [Etoposide results in increased expression of XRCC1 mRNA]; U 0126 inhibits the reaction [Etoposide results in increased expression of XRCC1 protein]
XRCC1 protein affects the susceptibility to Etoposide
Etoposide results in increased expression of XRCC1 mRNA; Etoposide results in increased expression of XRCC1 protein

NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701